Empowering Patients Using Smart Mobile Health Platforms: Evidence From A Randomized Field Experiment

Anindya Ghose
Stern School of Business
New York University

Xitong Guo
School of Management
Harbin Institute of Technology

Beibei Li
Heinz College
Carnegie Mellon University

Yuanyuan Dang
School of Management
Harbin Institute of Technology

Dec. 2020
(Forthcoming at MIS Quarterly)

Abstract

With today’s technological advancements, mobile phones and wearable devices have become extensions of an increasingly diffused and smart digital infrastructure. In this paper, we examine the emerging mobile health (mHealth) platform and its health and economic impacts on the outcomes of diabetes patients. To do so, we partnered with a major mHealth firm that provides one of the largest mobile health app platforms in Asia specializing in diabetes care. We designed and implemented a randomized field experiment based on 9,251 unique observations on blood glucose values and 55,359 unique observations on detailed patient health activities (e.g., steps, exercises, sleep, food intake) and app usage logs from 1,070 diabetes patients over three months together with a follow-up survey after five months. Our main findings show that mHealth technology adoption can lead to a reduction in patients’ blood glucose and glycated hemoglobin levels, hospital visits, and medical expenses of diabetes patients over time. Patients who adopted the mHealth application undertook higher levels of daily exercise, consumed healthier food with lower daily calories, walked more steps and slept for longer times a day. Our findings suggest that mHealth technology can help patients self-regulate their health behavior. This can lead to long-term behavioral modifications towards a healthier dietary and life style, which ultimately leads to an improvement in their health outcomes (e.g., glucose values, hospital visits). Interestingly, we also found personalized mobile message with patient-specific guidance showed an inadvertent effect on patient app engagement, life style changes, and health improvement due to stress, which in turn, can demotivate patients from self-regulating behavior. Overall, our findings indicate the potential value of mHealth technologies, as well as the importance of mHealth platform design in achieving better healthcare outcomes.

Keywords

mHealth, mobile app, healthcare platform, chronic disease, diabetes, personalization, patient self-management

1 Authors have equal contribution.
2 To whom correspondence may be addressed: Beibei Li (beibeli@andrew.cmu), Xitong Guo (xitongguo@hit.edu.cn).
1. Introduction

Facilitated by emerging smart mobile health (mHealth) technologies, the healthcare ecosystem is currently undergoing a disruptive, digital transformation in transitioning from reactive care to proactive and preventive care that can potentially be administered more cost-effectively (Wactlar et al. 2011). As defined by Estrin and Sim (2010), mHealth is the combination of mobile computing, medical sensor, and communications technologies used for healthcare services, including chronic-disease management and wellness. mHealth includes medical applications that may run on smartphones, tablets, sensors that track vital signs and health activities, and cloud-based computing systems for collecting health data. Indeed, mHealth technologies have demonstrated tremendous potential in shaping the healthcare industry toward a new era of evidence-based medicine and “Quantified Self” (QS)—individuals engaged in the self-tracking of biological, physical, behavioral, and environmental information (e.g., McKinsey 2013, Clark 2014). The global mHealth market will reach $49 billion by 2020, growing at a rate of more than 47% between 2013 and 2020.\(^3\)

Given the importance of health behaviors to well-being, health outcomes, and disease processes, mHealth technologies can provide great potential to facilitate patient lifestyle and behavior modification through patient education, improved autonomous self-regulation and perceived competence. Prior literature showed the pivotal role of behavior, intrinsic motivation and self-determination in well-being, morbidity and mortality, as well as healthcare costs (Schroeder 2007, Ryan et al. 2008, Patrick and Williams 2012, Deci and Ryan 1985, 2000). The accessibility, convenience, and ubiquity inherent to mobile devices can help patients easily upload information on a regular basis and follow the guidance that would eventually lead to improved health conditions.

However, although there is tremendous promise, uncertainty exists regarding whether mHealth can indeed improve patient health and behavior outcome, for a number of reasons.

---

3 [http://www.grandviewresearch.com/industry-analysis/mhealth-market](http://www.grandviewresearch.com/industry-analysis/mhealth-market)
First, although mHealth technologies can facilitate easy medical communication and interventions for patients, too frequent interventions might lead to annoyingness or habituation (Pop-Eleches et al. 2011). Second, health information that is inconsistent with patients’ prior belief or perceived as non-credible may be less persuasive and lead to potential information avoidance (Klein and Stefanek 2007, Harle et al. 2008, Harle et al. 2012). Third, the increased pervasiveness of personal behavioral tracking may bring potential privacy concerns to the users. Previous studies show patients might perceive highly personalized mobile SMS messages as intrusive (e.g., Pop-Eleches et al. 2011).

Furthermore, frequent personalized messages can also cause patients to feel pressured or coerced by intrapsychic or interpersonal forces. Such perceived control and judgment can significantly demotivate patient behavior from being autonomously self-regulated and lead to lower level of engagement and healthy activities. In particular, prior theories on self-determination (Self-Determination Theory (SDT)) and cognitive evaluation (Cognitive Evaluation Theory (CET)) have demonstrated that lack of choiceful and volitional feeling can lead to loss of autonomy and self-motivation (Deci and Ryan 1985, 2000). It in turn can lead to a significant decrease in patient intrinsic motivation of self-management—demotivate patient behavior from being autonomously self-regulated in health. Such loss of autonomy can lead to lower patient engagement in the health self-management process (e.g., lower mHealth app usage, lower patient-physician engagement, lower compliance to medication and treatment). Also, prior research showed that pressured evaluations and imposed goals diminish intrinsic motivation because they conduce toward an external perceived locus of causality (Deci & Ryan, 1985). Therefore, frequent and advanced personalization enabled by mHealth technologies might backfire patients’ engagement in health self-management.

Finally, from a methodological perspective, measuring the effectiveness of mHealth technology on patient health and behavior outcomes can be rather challenging. To date, very little knowledge has been developed toward evaluating the effectiveness of the mHealth applications (e.g., Lee 2014,
Archival analyses using secondary data may not work due to the potential patient self-selection bias in mHealth technology adoption, as well as patient heterogeneity and high dropout rate in mHealth technology usage. Hence, these issues call for a scientific, rigorous approach to evaluate and quantify the effectiveness of the mHealth platforms.

The above challenges motivate us to ask the following research questions in this paper: How does emerging technology persuade individuals to modify behaviors to comply with a new set of behavioral norms necessary to attain goals? More specifically, in the context of healthcare, how does mHealth technology persuade patients with chronic diseases to make behavioral modification to comply with therapy, and what is the corresponding impact on patients’ healthcare outcomes?

In particular, the healthcare outcomes we are interested in include patients’ health behavior and health outcome over time, as well as patients’ hospital visits and medical expense over time. We aim to explore whether and how smart mHealth platforms can empower patients and facilitate patients’ self-management with the chronic diseases. We are also interested in examining whether the mHealth platforms can help reduce patients’ hospital visits and medical expenses and thereby affect the operational costs of patients and healthcare providers.

Furthermore, to disentangle the underlying mechanism that drives the observed health outcome, we also look into the detailed patient activities, such as daily walking steps, exercise time, sleeping pattern and food intake, documented through the app, together with the detailed app usage data. This enables us to understand how patients actually use the mHealth app, what kinds of behavioral modifications occur in response to the app usage, and the underlying mechanism. Note that looking into the detailed patient activities and app usage logs can help us understand not only whether or not, but also why mHealth technologies can help improve the healthcare outcomes over time. This is one unique aspect of our work, which distinguishes it from the existing work in this area.
To achieve our goal, in this paper, we instantiate our study within the context of mHealth application for diabetes care. Diabetes is a chronic illness with significant health consequences that lead to macro- and microvascular complications, including heart disease, stroke, hypertension, nephropathy, and neuropathy. The American Diabetes Association (ADA) estimates that 25.8 million children and adults in the United States in 2011 had type 1 or type 2 diabetes. Diabetes poses a heavy economic burden on the US health care system, with estimated associated costs in 2007 of $174 billion (CDC 2012). Worldwide, high blood glucose kills about 3.4 million people annually. WHO projects diabetes deaths will double between 2005 and 2030.\(^4\) Therefore, proper patient education and self-management are pivotal, especially for those who are unable to adhere to the complex treatment regimen. However, self-management tasks such as regular medication and insulin use, frequent blood sugar checks, strict diet management, and consistent exercise can be quite challenging. Hence, the potential for mHealth applications, to help improve patients’ adherence to these behaviors through long-term engagement is great. Nevertheless, beyond diabetes care, our methodologies and insights have the potential to be generalized to other chronic disease or wellness contexts.

In particular, to evaluate the effectiveness of mHealth applications on diabetes patients’ behavior and health outcomes, we partnered with a major mHealth company in Asia that provides the nation’s largest mHealth app platform that specializes in diabetes care. We designed and implemented a randomized field experiment based on 9,251 unique observations on blood glucose values and 55,359 unique observations on detailed patient health activities (e.g., steps, exercises, sleep, food intake) and app usage logs from 1,070 diabetes patients over three months together with a follow-up survey after five months. We recruited our participants on a rolling basis. The entire study spanned from May 1, 2015, to July 31, 2016. By randomly assigning patients to different groups (e.g., adoption vs. no adoption of mHealth application), we are able to measure the treatment effect from a causal

\(^4\) [http://www.euro.who.int/en/health-topics/noncommunicable-diseases/diabetes/data-and-statistics](http://www.euro.who.int/en/health-topics/noncommunicable-diseases/diabetes/data-and-statistics)
perspective. Moreover, to evaluate the potential economic impact of the mHealth platform on patients’ medical costs and hospital visits, we conducted additional surveys and telephone interviews before and after the experimental period.

Our main findings are as follows. First, the adoption of the mHealth platform demonstrates a statistically significant impact on reducing the blood glucose and glycated hemoglobin levels\(^5\) of diabetes patients over time. The mHealth platform also has a statistically significant impact on reducing hospital visits and medical expenses for diabetes patients.

Second, the mHealth platform shows a 21.6\% stronger impact on patients’ health outcome than does the web-based platform (i.e., PC version of the application) that provides the same functions for diabetes management. This finding builds on the prior literature on the differences between PC and mobile devices (e.g., Xu et al. 2016), indicating an edge that mobile devices have over PC in affecting patients’ health behavior because mobility allows a user to respond more flexibly to real-time information (Ghose et al. 2013).

Third, the mHealth platform also demonstrates a significantly stronger impact on patients’ dietary and lifestyle improvement as well as engagement with app usage than does the web-based platform. Interestingly, we found that patients who adopted the mHealth application did significantly higher level of daily exercise, consumed healthier food with lower daily calories intake, walked more steps and slept for longer time a day. Our results suggest that mHealth technology can help patients become more autonomously self-regulated with their health behavior. Such increasing intrinsic motivation can help patients become more engaged, persistent and stable in their health activities, leading to long-term behavioral modifications towards a healthier dietary and lifestyle, which

\(^5\) Glycated hemoglobin is a form of hemoglobin that is measured primarily to identify the three-month average blood glucose concentration. Whereas blood glucose is a real-time measurement of blood sugar level. In diabetes research, both measurements are commonly used in evaluating both long-term and real-time blood sugar levels. The reference healthy range for Glucose is recommended to be between 3.9 and 7.1 mmol/L (Millimoles Per Litre). In 2010, the American Diabetes Association Standards of Medical Care in Diabetes also recommended Glycated hemoglobin to be lower than 6.5 mmol/L. 
ultimately leads to an improvement in their health outcomes (e.g., glucose values, hospital visits). This finding provides strong evidence of the underlying mechanism that drives the health outcome.

*Fourth*, in conjunction with patient self-management through the mHealth platform, we find heterogeneous effects between personalized and non-personalized messages. Interestingly, paired with all the health-management functions and resources provided by the mHealth platform, non-personalized SMS message interventions with general guidance about diabetes care demonstrate on average the highest effect on reducing patient glucose over time, 18.2% higher than personalized SMS message interventions with patient-specific medical guidance and 7.9% higher than no mobile message intervention at all.

Moreover, personalization is not as effective as non-personalization if we try to improve diabetes patients’ engagement with the app usage or general life style (i.e., sleeping behavior or movement habits). This is likely because patients might perceive frequent personalized SMS messages as intrusive and annoying (Pop-Eleches et al. 2011). More importantly, frequent personalized messages might cause patients to feel pressured or coerced by intrapsychic or interpersonal forces, which can significantly demotivate patient behavior from being autonomously self-regulated (Deci and Ryan 1985, 2000). These findings are surprising and suggest personalized messaging may not always work in the context of mHealth, and the design of the mHealth platform is critical in achieving better patient health outcomes.

The major contributions of our study are as follows. *First*, to the best of our knowledge, our study is among the first research to examine the effectiveness and mechanism of the mHealth application platform on chronic-disease management. To disentangle the underlying mechanism that drives the observed health outcome, we investigated the detailed patient activities, such as daily walking steps, exercise time, sleeping pattern and food intake, documented through the app, together with the detailed app usage data. This step enables us to understand how and why mHealth
technologies are able to lead to improved healthcare outcomes through patients’ behavioral modifications.

*Second*, by partnering with a major mHealth platform as a real-world testbed, we design and conduct a randomized field experiment. This step enables us to identify and measure the impact of mHealth on patient health from a causal perspective, by eliminating the potential self-selection bias in mHealth technology adoption. Moreover, our randomized experiment was conducted on a relatively large scale (with eligible sample size n=1070), over three-month treatment period together with a follow-up after five months. This experimental design allows our findings to be more rigorous than most prior research that was conducted via smaller-scale pilot studies, over a shorter study period, or without follow-ups in the long run.

*Third*, this study also presents a unique opportunity to examine the potential economic impact of mHealth technologies on the efficiency of healthcare management.

*Fourth*, our research provides important insights on mHealth platform design through a better understanding of patient health behavior and interactions with the platform. Such knowledge can be highly valuable for healthcare mobile platform designers and policy makers to improve the design of smart and connected health infrastructures through sustained usage of the emerging technologies.

The rest of this paper is organized as follows. Section 2 discusses the related literature. Section 3 describes in detail how we design the randomized field experiments and how we partner with the real-world testbed to carry out the experiment on a large scale. Section 4 describes the experimental data. Section 5 discusses how we analyze the data as well as our final results. Section 6 discusses further analyses on patient activities and app usage to understand the underlying mechanism that drives the observed healthcare outcomes. Section 7 discusses additional robustness tests. Finally, Section 8 concludes with potential future directions.
2. Literature Review

2.1 Impact of Healthcare IT

Our work is related to prior literature on the impact of healthcare IT. Recently, with the development of healthcare IT technologies and digital platforms, researchers have looked into the digital transformation of healthcare (e.g., Agarwal et al. 2010, Bardhan et al. 2015, Liu et al. 2019). Recent work has looked into the impact of healthcare IT,\(^6\) including the associated efficiency and financial performance (e.g., Ayal and Seidmann 2009, Hitt 2010, Hydari et al. 2015), adoption of healthcare IT in patient diagnosis, healthcare delivery, and treatment (e.g., Bhattacherjee et al. 2007, Angst et al. 2010), hospital performance (e.g., Menon et al 2000, Campbell et al. 2006, Amarasingham et al. 2009, McCullough et al. 2010, Miller and Tucker 2011, Aron et al. 2011, Das et al. 2011), hospital-level adoption and diffusion of healthcare IT (e.g., Angst et al 2010, Zheng et al 2005). At hospital-level, the evidence seems to be largely consistent that healthcare IT has a positive impact on hospital outcomes, including healthcare quality and efficiency (Buntin et al. 2011).\(^7\)

More recently, there is a growing interest in the consumer perspective of healthcare IT (e.g., Agarwal and Khuntia 2009, Gao et al 2010, Bardhan et al. 2015, Liu et al. 2019, Yan and Tan 2014). Recent studies have examined the impact of healthcare IT on patient care outcomes (e.g., Anderson and Agarwal 2011, Cebul et al. 2011, Bardhan and Thouin 2013). For example, Bardhan et al. (2015) focused on a chronic condition (congestive heart failure (CHF)) and examined health IT usage in relation to visits and readmissions. They found the adoption of health IT is associated with a reduction in the readmission risk of CHF patients. Interestingly, the evidence thus far for the impact of healthcare IT on patient care outcomes is equivocal, with prior research reporting positive, negative, and

---

\(^6\) For survey of recent work on the impact of healthcare IT, please refer to, for example, Agarwal et al. (2010) and Buntin et al. (2011).

\(^7\) A small number of studies reported unintended adverse consequences of health IT in hospital-level performance (Campbell et al. 2006), such as a sudden increase in mortality rates after implementation of computerized provider order entry (Han et al. 2005).
nonexistent effects (Agarwal et al. 2010, Bardhan et al. 2015). This, to a large extent, is due to the limitation in data deficiencies and limitations in the econometric estimation methods (Bardhan et al. 2015). These discrepant findings call for plausible explanations and present important opportunities for further work, especially from the patient care perspective.

Recently, studies have also focused on the social perspective and online healthcare platform design (e.g., Kane et al. 2009, Gao et al. 2012, Liu et al. 2019, Yan and Tan 2014, Yan 2020). For example, using data from RateMDs.com, Gao et al. (2012) examined the trends in patients’ online ratings for physicians over time and across specialties to identify what physician characteristics influence online ratings, and to examine how the value of ratings reflects physician quality. Liu et al. (2019) proposed an interdisciplinary lens that synthesizes deep learning methods to examine user engagement with encoded medical information in YouTube videos. They found videos with low medical information result in non-engagement; at the same time, videos with a greater amount of encoded medical information struggle to maintain sustained attention driven engagement. Yan and Tan (2014) investigate the role of social support from online healthcare community in patients’ mental health. They found that patients benefit from learning from others. Yan (2020) further studies how online communities can better design social tools to facilitate communication and establish a variety of relationships between users.

In addition to the above, our paper is related to a stream of literature regarding the impact of healthcare IT on patient self-management of disease (particularly chronic disease). For example, Lancaster et al. (2018) has reviewed the use and effects of recent electronic health (eHealth) tools (including: linked to electronic medical record, personal health record, web-based surveys and drug list, web-based access to lab results, patient educational resources, patient-clinician messaging) for

---

8 For a review of recent studies on patient self-management, Allegrante et al. (2019) provided a systematic analysis of selected outcomes from randomized controlled trials of chronic disease self-management interventions contained in 10 Cochrane systematic reviews, which provided additional evidence to demonstrate that self-management can improve quality of life and reduce utilization across several conditions.
patient self-monitoring. They found consistent evidence that the use of eHealth tools can lead to improvement in patient symptoms. However, little evidence was found to support the effectiveness of eHealth tools at improving patient self-efficacy and self-management of chronic disease. And no evidence was found towards medication recommendations and reconciliation by clinicians, medication-use behavior, health service utilization, adverse effects, quality of life, or patient satisfaction (Lancaster et al. 2018).

Our study builds on this prior set of literature on the impact of healthcare IT. We distinguish our study by focusing specifically on the novel context of mHealth technology, and examine its impact from the patient care perspective, including patients’ engagement with mHealth applications, patients’ self-efficacy and self-management of chronic disease, patients’ behavior modification and health outcome, and patients’ healthcare costs. We also focus on understanding both the immediate impact (upon adoption and usage) and long-term impact (three to eight months after the adoption and usage).

2.2 Mobile Health (mHealth) and User Behavior

Our paper is also related to the recent work on mHealth and how it can change user behavior and adherence to medical treatment. Several recent studies have successfully piloted programs based on mobile SMS text messages, targeting patients with asthma, obesity, smoking, HIV/AIDS, and diabetes (e.g., Krishna et al. 2009, Lester et al. 2010, Pop-Eleches et al. 2011, Nundy et al. 2014). They have found an impact from mobile SMS messaging on user health behavior; however, the content, intensity, and delivery mode of the SMS messaging seem to have a significant influence on the effectiveness of the mHealth interventions (Free et al. 2013).

For example, Pop-Eleches et al. (2011) conducted a randomized trial using mobile SMS interventions in Kenya to test the effect of mobile SMS reminders on the adherence to HIV treatment. They found simple weekly reminder messages (without any additional counselling) can significantly improve adherence. But surprisingly, more frequent daily messages do not improve patient adherence,
because of potential habituation or intrusion. They also found adding more personal words, such as words of encouragement, in the longer text messages was not more effective than either a short reminder or no reminder.

More recently, studies have looked at the stand-alone mHealth app as tools for user health self-management (e.g., Maged et al. 2014). Several recent studies surveyed the design and guidelines of existing mHealth (particularly, diabetes self-management) apps in the mobile market.

For example, Demidowich et al. (2012) have surveyed the existing diabetes apps on the Android platform and found they offer a variety of functions, including self-monitoring blood glucose recording, medication or insulin logs, and prandial insulin dose calculators.

Nes et al. (2012) studied the development and feasibility of intervention for diabetes patients with diaries and situational feedback via smartphone apps, which integrated communication between patients and a healthcare provider, allowing for the patient to log blood sugars, daily eating behaviors, medication compliance, physical activity and emotions into the mobile diary.

Brzan et al. (2016) conducted a systematic review of 65 free apps in the English language for smartphones in three of the most popular mobile app stores: Google Play (Android), App Store (iOS) and Windows Phone Store. Three independent experts in the field of healthcare-related mobile apps were included in the assessment for eligibility and testing phase. The authors found 56 of these apps did not meet even minimal requirements or did not work properly, calling for a need for mobile apps for self-management of diabetes with more features in order to increase the number of long-term users and thus influence better self-management of the disease.

Arnhold et al. (2014) have carried out a systematic review of 656 currently available diabetes apps for the operating systems iOS and Android. The study considered the number of newly released diabetes apps, range of functions, target user groups, languages, acquisition costs, user ratings, available interfaces, and the connection between acquisition costs and user ratings. Additionally, it
examined whether the available applications serve the special needs of diabetes patients aged 50 or older by performing an expert-based usability evaluation. The study found that although a vast number of diabetes apps already exist, but the majority offer similar functionalities and combine only one to two functions in one app. Multifunctional apps performed considerably worse in terms of usability.

Similarly, Sieverdes et al. (2013) have conducted a review of the guidelines for diabetes care and mHealth related to glycemic control and self-monitoring of blood glucose, pharmacological approaches and management, medical nutrition therapy, physical activity and resistance training, weight loss, diabetes self-management education and blood pressure control and hypertension.

A recent survey by Wang et al. (2017) systematically searched PubMed for mHealth-related studies on diabetes and obesity treatment and management published since 2000. They found existing studies in this area mainly focused on examining the impact from three major types of mHealth interventions: mobile phone text messaging, wearable or portable monitoring devices, and smartphone apps. They also noted that most existing studies included only small samples (<60 subjects per group) and short intervention periods (<3 months, no follow-up) and did not use rigorous data collection or analytic approaches. Although some studies suggest that mHealth interventions are effective and promising, most are pilot studies or have limitations in their study designs. There is an essential need for future studies that use larger study samples, longer intervention and follow-up periods to provide comprehensive and sustainable support for patients and health service providers.

Similar to our paper, a few recent studies also focused on examining the impact of diabetes smartphone app on patient health using randomized controlled trials. However, the main outcomes these studies focused on tend to be wellness-centric, such as patient weight loss (Allen et al. 2013, Martin et al. 2015) or food intake (Nollen et al. 2014). Instead, our study focuses on healthcare-centric outcomes including blood glucose, hospital visits and medical expenses. Moreover, we also investigate various behavioral outcomes including patient activities and app usage to disentangle the underlying
mechanism that drives the observed health outcomes. This is one unique feature of our study which distinguishes it from all existing studies.

Another study similar to ours is Rossi et al. (2009). The authors examined the impact of a mobile application “Diabetes Interactive Diary” on Type I diabetes patients. They found the app was perceived to be safe, helpful, and easy to use by the patients. However, they found the app was associated with a non-statistically significant reduction in blood glucose based on a 9-month follow-up study with 41 patients. Our study is significantly different from Rossi et al. (2009) in research context, goal, methodology, and study scale (sample size): (i) Our study focused mainly on Type II diabetes which, different from Type I diabetes, is directly tied to dietary or lifestyle self-management; (ii) Our goal is to understand the causal impact of mHealth app on diabetes patient health outcomes, as well as the underlying mechanism of how such technology can persuade patients to modify their behaviors to achieve these outcomes; (iii) our research method was based on randomized controlled trial, whereas Rossi et al. (2009) relied on a quasi-experiment approach to follow up the same group of patients and compare the health outcomes; (iv) our study was conducted based on a much larger scale (sample size n=1070), which allow our study to be much more rigorous than many existing pilot studies.

Besides, some recent studies focused on mHealth apps from the exercise, weight loss, and wellness category. The built-in camera, standard in smartphones today, allows users to record a photo diary of daily food and drink (Maged et al. 2014). Lin et al. (2016) have studied the impact of mobile-based visual diaries and peer engagement through the app “MyPlate” on user eating behavior. The authors have found a strong positive impact of the mobile-based visual diary and dietitian support on improving customer engagement. Using a unique dataset from a freemium mobile weight management application, Uetake and Yang (2017) have investigated the role of short-term goal achievement on long-term outcomes and future customer development under the context of weight loss. They have also found the impact of short-term goal achievement varies across user segments. Compared with these
studies, our work distinguishes itself in its focus on mHealth app and chronic disease care (particularly diabetes), to examine the causal impact on patient behavior, medical expense, and health outcome.

2.3 Mobile App Market and User Engagement

In addition, our study is related to prior research in the context of the mobile app market (e.g., Bresnahan and Greenstein 2014). Recent research from the IS, Marketing, and Economic communities has evaluated the mobile app demand in two-sided markets (e.g., Garg and Telang 2013, Ghose and Han, 2014, Lee and Raghu 2014, Han et al. 2016), platform choice for mobile app developers (e.g., Bresnahan et al. 2014), user engagement in mobile apps (e.g., Zhang et al. 2018, Kwon et al. 2016), product innovation and development in the mobile app market for cross promotion (Lee et al. 2014), copycat detection (Wang et al. 2018), or service system innovation (Eaton et al. 2015). However, very little research has focused on the healthcare mobile app platform and the associated impact on consumer behavior. This is the main focus of our paper.

2.4 Chronic Disease and Diabetes Care

Finally, our work is related to prior studies on chronic-disease management, especially diabetes care. There have been a tremendous amount of studies on diabetes care, mainly from the medical community (e.g., Mohammed et al. 2013). The development of medical treatment is beyond the scope of this paper. However, our study builds on this prior literature, and in particular, we focus on the design and impact of personalized diabetes care and patient self-management enabled through the mHealth app platform. According to a recent study at Cell, researchers continuously monitored week-long glucose levels in an 800-person cohort, measured responses to 46,898 meals, and found high variability in the response to identical meals, suggesting universal dietary recommendations may have limited utility and that personalized diets may successfully modify elevated postprandial blood glucose and its metabolic consequences (Zeevi et al. 2015). The mHealth app platform offers a unique, personalized channel for patient self-management.
3. A Randomized mHealth Field Experiment

To evaluate the effectiveness of the mHealth app on patients’ behavior and health outcomes, one could collect secondary app user data and examine the user health behavior before and after the app adoption. However, the critical challenge for such an archival data analytical approach is the potential (strong) self-selection bias in the app user population. For example, users who care more about their health will be more likely to adopt the mHealth app, and will be more likely to change their behavior and lifestyle in a healthier direction. This self-selection could lead to a statistically significant and positive correlation between the app adoption/usage and user health over time. However, this positive relationship might be endogenous, because of the unobserved user-level attributes that lead to the app adoption/usage in the first place.

Therefore, ideally, we would like the users to be randomly assigned to use the mHealth app—those who use the app and those who do not use the app will show no significant difference statistically. If so, the difference in their health behavior change before and after the app adoption would be attributed solely to the impact of the app adoption/usage over time. Unfortunately, using only secondary data, we cannot easily identify such an impact from a causal perspective.

To ensure the random assignment of users, we propose to design and implement a randomized field experiment by partnering with a major mHealth company in Asia that provides the largest mHealth app platform in the nation that specializes in diabetes care. In this section, we will first introduce the background of this mHealth app platform. Then, we will discuss in detail how we design and implement our experiment.

3.1 Mobile Health Platform Background

Our research partner is a major mHealth firm in Asia. It provides the largest mHealth platform for chronic-disease management, specializing in diabetes care. To date, the mobile platform has 156,120 active users and 9,970 affiliated physicians who specialize in diabetes care across the nation.
In addition to the external expert network, the platform also has a full-time internal expert team with more than 20 medical professionals including physicians, pharmacists, nurses, psychologists, and nutritionists. The platform integrates all the medical resources into a mobile app for patients.

This patient app provides diabetes patients with 24/7 services with four sets of core functions to facilitate patient self-management: (1) Behavior Tracking: patients can record and upload at any time their blood glucose, blood pressure, exercises, diet, weight, sleep, and so on. (2) Risk Assessment and Personalized Solutions: a cloud-based backend data analytic system will analyze individual patients’ data and assesses the real-time health risk for each patient by taking into consideration 45 different types of medical conditions, including the stage and type of diabetes, whether the patient is pregnant, whether the patient has a complication, and so on. Based on the data analytic results, the app will recommend personalized self-management solutions for each patient regarding diet, exercise, lifestyle, and potential medication. To ensure the validity of the recommendation, the internal medical team will view and discuss the data analytic results and personalized solutions regularly to improve the algorithm. (3) Q&A: the patients can contact the physicians in the internal and external expert networks for free consultation at any time regarding the medication, treatment, or self-management of their health. (4) Patient Community: the patients can participate in a digital community through the mobile app platform to discuss and communicate with each other.

For a better understanding of the patient app function, we provide screenshots of the major functions in Figure A1 in Appendix A. In particular, (1a) illustrates the overview of the user homepage after login. (1b) illustrates the page of recording a new blood glucose value. (1c) illustrates a set of user behavior tracking pages that visualize blood glucose, blood pressure, diet, and exercise. In addition, we also provide more screenshots for other related app functions in Figures A3 and A4 in Appendix A.
One critical challenge from the app platform designer’s perspective is to examine how effective the app is in actually improving the patient health behavior and outcomes over time. To achieve this goal, we designed a large-scale randomized field experiment, which we discuss next.

3.2 Experiment Design and Implementation

We designed and implemented a nationwide large randomized field experiment by partnering with the firm. Our national campaign for the event received widespread attention from the society. To examine the impact of the mHealth platform under various situations, we designed five experimental conditions (2 Control groups + 3 Treatment groups) as follows:

- Control Group (C1): No treatment, behave as usual;
- Control Group (C2): Use the web (PC) version of the health app;
- Treatment Group (T1): Use the mHealth app;
- Treatment Group (T2): Use the mHealth app + Receive non-personalized SMS reminder messages with general knowledge about diabetes care twice a week; and
- Treatment Group (T3): Use the mHealth app + Receive personalized SMS reminder messages with patient-specific health advice from the internal expert team twice a week.

Control group C1 is the baseline. Control group C2 is a second baseline to examine the potential device effect that can lead to differences in the effectiveness of the diabetes self-management application. Treatment group T1 contains the normal mHealth app users who have access to all four sets of app functions. We designed treatment group T2 to test the potential synergetic effect when the mHealth app is paired with the mobile SMS messaging; research has shown the latter alone to be effective in improving patient treatment adherence and health outcomes (e.g., Lester et al. 2010). Finally, we designed treatment group T3 to further test the potential impact from the design of the SMS messaging, which were shown to have a significant influence on the effectiveness of the mHealth interventions (Pop-Eleches et al. 2011, Free et al. 2013). We provide an example of the two types of mobile SMS messages in Figure A5 in Appendix A.
We recruited participants for our experiment based on a voluntary basis through a combination of channels, including announcements through several national major news websites, social media and social networks via both web and mobile platforms, as well as offline recruiting through local hospitals and communities. Upon registration, each participant was randomly assigned to one of the five experimental groups. As compensation for their time and efforts, participants were automatically enrolled in a lottery upon completion of the experiment. The potential rewards from the lottery included Apple Watch, Fitbit smart bands, blood glucose meters, air purifiers, or gift cards with various values (from $5 to $750).

The initial round of participant recruitment started in May 2015. One practical challenge in medical trials is the potential delays in recruitment and the high rates of dropout, which might lead to uncertainty in the treatment effectiveness and might confound results (e.g., Watson and Torgerson 2006, Gupta et al. 2015). To ensure an effective sample size, we conducted the experiment by recruiting participants on a rolling “first-come-first-served” basis until the target sample size was met. Such an approach is common in medical trials (e.g., Gupta et al. 2015, Yeary et al. 2017, Myerson et al. 2018). Overall, the recruitment period spanned over seven months, from May 2015 to Dec 2015. To guarantee that long recruitment window would not introduce any confounding factors caused by time trend, we conducted an additional sub-sample analysis by selecting a subset of control and treatment groups who were recruited into our experiment during the same month. We provide more details on this analysis in Section 7 for robustness checks.

The treatment period of the experiment lasted for three months (90 days) starting from the day of registration. Based on the random assignment to the experimental group, each participant received the corresponding treatment according to the experimental design during the treatment period. In addition, to collect patient-level demographics and medical history, as well as to evaluate the potential economic impact of the mHealth platform on patients’ medical costs and hospital visits, we conducted
additional surveys through telephone interviews before and after the treatment period. In particular, we interviewed each participant twice—first at the beginning of the experiment (during registration) and again five months after the last day of the treatment period. Therefore, for each participant, the total experimental period lasted for eight months (i.e., pre-treatment survey + 3-month treatment period + 5-month post-treatment period + post-treatment survey). Overall, the entire study for all our participants spanned 15 months from May 2015 to July 2016. The last batch of participants was recruited in December 2015. They completed the experiment and surveys by the end of July 2016.

During the two telephone interviews for the pre- and post-treatment surveys, we asked the participants about their demographics, medication and medical history, most recent blood glucose and glycated hemoglobin levels, frequency of hospital visits, medical costs, and so on. Informed consent was obtained at each phase of the study that required data collection. In the next section, we will discuss in more detail the exact survey variables we collected.

Note that to eliminate potential confounding factors, during the experimental period we ensured the following facts: (1) no participant had previously adopted the mHealth app prior to the registration to our experiment; (2) participants who were assigned to the two control groups did not happen to adopt the mHealth app during the experiment on their own. (We validated these first two facts by crosschecking the phone numbers between the participants and the mHealth app adopters in the company database, and also through the post-treatment survey to exclude those who were not supposed to be adopters of the app prior or during the experiment.) (3) participants did not adopt other similar apps during the experiment. (We validated this fact through the post-treatment survey to exclude the potential impact from other similar apps.) Finally, to avoid potential bias due to misalignment with participants’ prior expectation, we followed prior social and behavioral research methods (Hoyle et al. 2001) and ensured that the recruitment announcement only revealed the general purpose of the

---

9 We provide the details about the pre- and post-treatment surveys in Appendix B.
experiment (i.e., to help improve diabetes care), whereas it did not reveal the exact details of the experiment (i.e., to study the impact of adoption of mHealth app on diabetes patient behavior).

4. Data

In this section, we will describe our data from both the experiment and the pre- and post-treatment surveys. We first illustrate our data sampling procedure during the recruitment and randomization processes. To validate our samples, we conducted the randomization check and briefly discuss it.

4.1 Randomization and Sampling

Our recruitment process led to the enrollment of 1,770 patients. To ensure minimum confounding factors, we excluded 427 (24.1%) patients from our sample who did not have diabetes (e.g., people whose blood glucose value was reaching the upper bound of the normal range but were not classified as diabetic yet), or had other major chronic disease(s) at the same time (e.g., kidney disease, heart disease, arthritis, HIV/AIDS), or were already users of the app. These exclusions led to a sample of 1,343 patients whom we randomly assigned into one of the five experimental groups. During the three-month treatment period, 273 (15.4%) patients dropped out. Hence, our final eligible sample for analysis contains 1,070 patients, 60.5% of the original enrolled sample. We illustrate the flow of the randomization and sampling procedure in Figure C1 in Appendix C.

Note that high patient dropout rate is a common challenge in medical trials (e.g., Gupta et al. 2015). To alleviate any additional concern towards this issue, we compared the distributions of participants’ demographic and baseline health-related characteristics between the dropout samples and the eligible samples. We did not find statistically significant difference between the two. We also compared the distributions of participants’ demographic and baseline health-related characteristics among all the dropout samples across the five experimental groups. We did not find statistically significant difference across the control and treatment groups regarding dropout samples. In Section 7,
we provide more detailed results on these tests. Therefore, while we acknowledge this fact as one potential data limitation in our study, we are more confident that it is not a serious concern in affecting our results.

4.2 Data Description

Our main experimental data contain a combination of three data sets:

(1) Panel data of individual health and behavior characteristics recorded through the mobile (or web-based) health application during the three-month treatment period. This information includes diabetes-related health activities such as glucose value, glucose type (e.g., pre-/post-breakfast, pre-/post-lunch, pre-/post-dinner, before sleep), and uploading time/date. Notice that for the control group (C1) that did not use the mobile or web-based health application, we asked the participants to upload their glucose values at least twice: at the beginning and end of the three-month treatment period through a web portal. We provide the screenshot of this web portal in Figure A2 in Appendix A.

(2) Panel data of individual activities and app usage logs. This information includes walking steps, exercise time and calories burned, food intake and estimated calories, sleeping time (starting and ending time, and length), app opening time and frequency, frequency of documenting activity logs, loyalty rewards, shopping activities (product purchased, price, order time), in-app Q&A with medical experts (query time, answer time). For some of the activities such as walking steps, the app can automatically log them through the build-in sensors of the smartphone. For other activities like exercise, sleep or food intake, they require the patients to document them in the app. Note that the patients only need to document (select from a pre-compiled list) the type of exercise/food and corresponding time/amount, the app can then automatically calculate the estimated calories burn/intake. For the purpose of understanding patient app usage behavior, we consider the frequency of

---

10 For patients in control group C2 (who were asked to document all the activities through the web-based application on the PC), it was difficult to record the walking steps by the patients themselves. Hence, we suggested them use information from any other movement tracker’s (such as iPhone’s inherent Health app or Xiaomi’s Mi Fit app) if they had any. We found two patients did not have such information. We excluded them later from the corresponding analysis on #steps.
documenting activity logs as the times only when patients document exercise, sleep and food activities in the app (instead of the automatic activity logs generated by the app).

(3) Survey data of individual demographics, health, and behavior characteristics from the pre- and post-treatment surveys. This information contains individual age group, gender, marital status, income level, diabetes type (i.e., type 1, type 2, gestational), diabetes age (time since diabetes was first diagnosed), frequency of glucose monitoring, whether the patient has any complications, the most recent blood glucose value and type, glycated hemoglobin for the most recent three months, average time for exercise and sleep per day during the most recent three months, average calories per meal during the most recent three months, whether the patient is a smoker or drinker, whether the patient is pregnant or not, current and past medication, medical history (e.g., blood pressure, blood fat, family history), frequency of hospital visits per year, frequency of hospital visits during the last three months, and medical costs during the last three months. The survey data also contain information on individual app-related activities including registration time/date, frequency of app daily usage, and satisfaction rate. For details on these variables, we provide the summary statistics in Table 1.

4.3 Randomization Check

To validate the randomization procedure, we conducted a randomization check. We provide the details about the randomization check in Table 2. Across the five experimental groups, we compared the distributions of the patient demographics and baseline health condition characteristics. We found the distributions are similar across groups. Furthermore, to better control for the potential variation in the patient-level characteristics, we tested several different models by including all or different subsets of these variables in our analyses as control variables. We found our results stay highly consistent. We will discuss more details in the next section.
5. Analysis and Findings

In this section, we discuss how we analyzed the experimental data to examine the impact of the mHealth platform on patient health behavior and outcomes. Note we have both the panel data on patient health and behavior characteristics during the three-month treatment period, and the cross-sectional survey data before treatment (upon registration) and five months after treatment. We first conduct a group-level analysis using the survey data to compare the difference in patient health and behavior before and after the treatment. Then, we use the panel data to conduct the analysis of the treatment effect at the individual level.

5.1 Group-Level Analysis

First, we conduct a group-level analysis using the survey data to compare the difference in patient health and behavior before and after the treatment. Note the total time period between the two surveys is eight months: a three-month treatment period plus a five-month post-treatment period. By doing so, we aimed to capture the potential long-term effect of the treatment. In particular, across the five groups, we compare the differences in the blood glucose and glycated hemoglobin levels, the number of hospital visits during the most recent three months, and the total medical spending related to diabetes during the most recent three months. We provide the details in Table 3. The values across groups are statistically different at the p<0.05 level based on the one-way ANOVA test.

The first thing we notice is that in the baseline control group (C1), the four variables stayed relatively stable before and after the treatment, whereas all other groups that used the health application (whether mobile- or web-based) showed a significant reduction in patient glucose and hemoglobin values, as well as a reduction in hospital visits and medical spending. This finding is promising. It indicates the health platform for diabetes self-management indeed has a significant effect on improving patient health outcomes as well as reducing costs.
Second, compared to the second baseline group (C2) with web-based health intervention, the three treatment groups with mHealth interventions (T1, T2, T3) experienced a statistically significantly higher impact on patient health and costs. For example, under the same functional setting of the health application, we observe a 21.6% increase in the mobile-based platform’s (T1) impact on reducing patients’ glucose, compared with the web-based platform’s (C2) impact. This result is consistent with previous findings indicating a significant mobile device effect (e.g., Xu et al. 2016, Wang et al. 2016). Such an effect can become salient in personal health management through faster and more flexible user response to real-time information and mobile-enhanced user self-efficacy (e.g., Lin et al. 2016).

Third, we notice that among the three mobile treatment groups, T2, when we paired the mHealth app with simple non-personalized SMS reminder messages about general guidance on diabetes care, demonstrates the strongest treatment impact on reducing blood glucose levels over time, 18.2% higher than personalized SMS message interventions with patient-specific medical guidance and 7.9% higher than no mobile message intervention at all. We also see a consistent trend in the Hemoglobin value. Interestingly, T3, when we paired the mHealth app with personalized SMS messages about patient-specific medical advice, does not perform better than non-personalized messages in helping patients improve their health outcome. This finding is surprising but highly consistent with prior research that the design of the SMS messaging has a significant influence on the effectiveness of the mHealth interventions (Free et al. 2013), and that more personal and encouraging words in longer text messages were not more effective than either a short reminder or no reminder, because of potential habituation or perceived intrusion (Pop-Eleches et al. 2011), and that personalization might lead to potential privacy concerns and information overload for consumers (e.g., Aral and Walker 2011, Goldfarb and Tucker 2011, Ghose et al. 2014).

Finally, when looking into the patient hospital visits and medical spending, we find T3 demonstrates the highest impact in reducing the two. T3 is 62.5% and 168.4% more effective compared
with T2, the next best treatment, in reducing hospital visits and medical spending, respectively. This result suggests the potential of the mHealth app combined with personalized SMS messaging to reduce the medical and operational costs for diabetes patients and healthcare providers. Although personalized messaging is not more effective in affecting patient health outcome than non-personalized messaging, it might facilitate a personal connection between patients and physicians, which can lead to increased patient trust in the mHealth platform, hence reducing patients’ need (or urge) to visit hospitals or take additional medication.

Note that all the analyses in this subsection are based on the cross-sectional survey data and are conducted at the group (mean) level. The impacts here should be interpreted as the group-level mean treatment effect. To further account for the potential heterogeneity within the group, we conducted individual-level analysis using the panel data, which we will discuss next.

5.2 Individual-Level Diff-in-Diff Analysis

To better control for the potential individual heterogeneity and explain the potential discrepancy in the observed outcome, we conduct individual-level analysis using the panel data of individual health and behavior characteristics we collected during the three-month treatment period. Because our recruitment is conducted on a rolling basis, we consider the time indicator in our context as the time elapsed since the patient started the experiment. Particularly, in our analysis, it is defined as the unique sequence index of each patient’s uploaded glucose value.

To account for the patient-level baseline time trend\textsuperscript{11}, we apply a diff-in-diff method to model individual-level glucose change over time. In particular, the first-level difference is the within-group glucose change over time (i.e., group-specific time trend), and the second-level difference is the discrepancy in this time trend across groups. Put more formally, we model the glucose value $Glucose_{it}$ for patient $i$ at time $t$ as follows:

\textsuperscript{11} We first examined the overall time trends in each experimental group regarding the blood glucose change over time at the individual patient level. We plot the glucose value over time for each group in Figure D1 in Appendix D.
Glucose_{it} = \beta_0 + \beta_1 Treatment_i + \beta_2 Time_t + \beta_3 Treatment_i \times Time_t + X_i \beta_4 + C_{it} \beta_5 + \epsilon_{it}, \quad [1]

where Treatment_i represents the indicators of the five experimental groups. Time_t represents the time indicator of how many days since the start of the treatment period when the corresponding glucose value was uploaded (1 \leq Time_t \leq 90).

\( X_i \) is a vector of control variables for patient-specific time-invariant characteristics including age group, gender, income level, marital status, diabetes type, diabetes age, frequency of glucose monitoring, whether the patient has any complications, most recent glucose and glycated hemoglobin levels prior to the experiment, average time for exercise and sleep per day and average calories per meal prior to the experiment, whether the patient is a smoker or drinker, whether the patient is pregnant, whether the patient has any other health concerns, such as high blood pressure or cholesterol, whether the patient is currently on any medications, and whether any patient-physician interaction occurred during the three-month treatment period.

\( C_{it} \) is a vector of control variables for patient-specific time-varying characteristics including the time of day (morning, afternoon, evening), day of the week (Monday ~ Sunday), and month indicators of the corresponding glucose uploading activity, uploaded glucose type, daily exercise from the patient (total steps), as well as the patient’s frequency of daily app usage (including all types of activities). \( \epsilon_{it} \) is a stochastic error to capture any randomness in patient behavior. The unobserved error term is assumed to be orthogonal to other independent variables and has a mean zero. In the estimation, we cluster the \( \epsilon_{it} \) at the experimental group level to account for potential within-group relationships.\(^\text{12}\)

We have tested different models (Models I ~ IV) with different combination of the set of control variables. We provide our estimation results from these models in Table 4. In the estimation, the primary coefficient of interest is \( \beta_3 \), which is a vector that contains coefficients for the four

\(^{12}\) We also tried to estimate the model without the clustered error, and found the results are highly consistent.
interaction effects ($Treatment_t \times Time_t$). Note the control group indicator C1 is dropped due to collinearity (i.e., the interaction effect between C1 and $Time_t$ will be captured as the baseline effect, $\beta_2$, the coefficient of $Time_t$).

All four models demonstrate similar estimation results and provide evidence consistent with our previous group-level analyses. First, we notice that all four groups (C2, T1, T2, T3) experience a significant reduction in patient glucose values. This finding indicates the diabetes self-management platform (whether mobile- or web-based) is effective compared with the baseline control group (C1) that did not use the platform.

Second, comparing T1 with C2, we notice a significant device effect: the mobile-based platform is more effective than the web-based platform in reducing glucose levels over time.

Third, when comparing the three treatment groups (T1, T2, T3), we see an interesting trend: T2 (the mHealth app with non-personalized mobile SMS reminder messages) is overall most effective in helping patients reduce their glucose over time, whereas T3 (mHealth app with personalized mobile SMS messages) is less effective. This observation is consistent with our findings from the group-level analyses as well as the prior literature (e.g., Harle et al. 2008, 2012), indicating the design of the mobile SMS messaging plays an important role in the effectiveness of the mHealth interventions on patient health outcomes (e.g., Free et al. 2013, Pop-Eleches et al. 2011). Carefully designing the content, format, intensity, and delivery mode of the SMS messaging is critical.

Finally, when looking at the baseline coefficients, we see the majority of the four baseline coefficients for the treatment groups ($\beta_1$) are not statistically significant. This finding further validates our random group assignment indicating the initial glucose values do not seem to vary significantly across groups. Moreover, when looking at the baseline coefficient for $Time_t$, we find $\beta_2$ is statistically significant and positive for all groups. This finding indicates the baseline time trend of patient glucose for control group (C1) without any intervention is increasing over time. This result delivers an
important message. It indicates the potential risk and challenge in diabetes care over time, and suggests the importance of empowering patients to improve their self-management for diabetes through smart and digital health platforms.

5.3 Patient-Level Fixed Effect

In the previous section, we considered a large number of patient-level characteristics in the individual-level analysis to control for individual-level heterogeneity. To further account for any other potential unobserved individual characteristics, we conduct the diff-in-diff analysis with patient-level fixed effects as follows:

\[
Glucose_{it} = \beta_0 + \beta_1 Time_t + \beta_2 Treatment_i \times Time_t + \mu_i + C_{it}\beta_3 + \varepsilon_{it},
\]

where \(\mu_i\) captures the patient-level fixed effect. Note that in this model, we drop the treatment group indicator \(Treatment_i\) and the patient-specific time-invariant characteristics \(X_i\) from the model because of collinearity with the patient fixed effect. The primary coefficient of interest is \(\beta_2\), the interaction between the treatment group indicator and time. We estimate the model with the patient-specific time-variant characteristics, \(C_{it}\) (Model V), and without, \(C_{it}\) (Model VI). The corresponding estimation results are shown in Table 5.

Overall, our findings from the patient-level fixed-effects model demonstrate high consistency with our previous analysis using the treatment-group-level fixed effect (i.e., equation [1]). We find the adoption of the mobile-based platform (T1, T2, T3) can statistically significantly improve the health outcome of diabetes patients in reducing their blood glucose values over time, even after controlling for the individual-level fixed effects.

Moreover, we also see a consistent trend: in conjunction with the mHealth app platform, non-personalized mobile messages with general guidance for diabetes care have a higher impact on patient health improvement than personalized mobile messages. These additional empirical analyses provide us with robust evidence in our results.
6. Further Analyses on Patient Behavioral Modifications

To disentangle the underlying mechanism that drives the observed health outcome, we further investigated the detailed patient behavioral activities, such as walking steps, exercise time, sleeping pattern and food intake, documented through the app, together with the detailed app usage data. This step enables us to understand how patients actually use the mHealth app and what kinds of behavioral modifications occur in response to the app usage. Note that looking into the detailed patient activities and app usage logs to study how exactly mHealth technologies can lead to patients’ behavioral modifications over time to achieve better healthcare outcomes is a unique feature of our work, which distinguishes it from all the existing work in this area.

6.1 Analyses on Patient Activity and App Usage

We conducted empirical analyses to study the impact of mHealth treatments on each of these patient activity and app usage outcome variables, using a Diff-in-Diff model with patient-level fixed effect. We provided the detailed estimation results in Tables 6a and 6b (Patient Activities) and Table 7 (App Usage). Note that because control group C1 did not have access to the health application, we did not have any individual-level activities or app usage data from these patients. In all the analyses below, control group C2 (who had access to the PC-based application) was used as the baseline for comparison.

More specifically, our main findings are the following. First, when looking into the patient activities as outcome variables (Tables 6a and 6b), we found that compared to patients from the PC group (C2), patients from the three mHealth treatment groups (T1, T2, T3) did significantly higher level of daily exercise, consumed healthier food with lower daily calories intake, walked more steps and slept for longer time a day. These findings indicate that patients indeed have made significant behavioral modifications towards a healthier dietary and life style after adopting and using the mHealth application. As seen from our results, patients in the mHealth treatment groups became more autonomously self-regulated with their health behavior. Such increasing intrinsic motivation helped
them become more engaged, persistent and stable in their behavior, leading to an improvement in their health outcomes (e.g., glucose values, hospital visits).

Interestingly, we found the three mHealth treatment groups performed relatively similarly in daily food calories intake from breakfast, lunch and dinner. However, we noticed a significant drop in the performance from T3, the patient group provided with additional personalized SMS reminder messages, with regard to daily walking, exercise and sleeping patterns. In particular, when combining mHealth app with personalized reminder messages (T3), it leads to a 33.1% decrease in the number of daily walking steps and a 28.8% decrease in total exercise time compared to using mHealth app alone (T1), and it leads to a 49.8% decrease in the daily steps and a 33.6% decrease in total exercise time compared to combining mHealth app with non-personalized reminder messages (T2).

Meanwhile, providing additional personalized reminder messages (T3) also leads to a 28.1% and a 43.8% decrease in daily sleeping length, compared to using mHealth app alone (T1) and providing additional non-personalized reminder messages (T2) respectively. Furthermore, when looking into the frequency of late night sleep – when patients went to sleep later than 11pm – we noticed that providing personalized reminder messages in conjunction with the mHealth app can lead to more frequent late night sleep by the patients.

These findings suggest that highly personalized messages may not always work well in trying to persuade patients’ behavioral modifications. As shown in our results, personalization is not as effective as non-personalization if we try to improve diabetes patients’ general life style (i.e., sleeping behavior or movement habits).

This is likely because patients might perceive frequent personalized SMS messages as intrusive and annoying (Pop-Eleches et al. 2011). More importantly, frequent personalized messages might cause patients to feel pressured or coerced by intrapsychic or interpersonal forces, which can significantly demotivate patient behavior from being autonomously self-regulated (Deci and Ryan 1985, 2000).
Second, when looking into the app usage as outcome variables (Table 7), we found that overall patients from the three mHealth treatment groups (T1, T2, T3) demonstrated a higher level of usage activities compared to the PC group (C2) – opening app and documenting their daily health activities more frequently, more frequent in-app communications with medical experts, and higher loyalty rewards. This finding indicates a strong positive impact of mobile platform on patient engagement with the healthcare technologies. Patients are more likely to engage with the health self-management functions provided in a more flexible setting (i.e., on mobile devices). The accessibility, convenience, and ubiquity inherent to mobile devices help patients easily upload information on a regular basis and follow the guidance that would eventually lead to improved health conditions.

Among the three mHealth treatment groups, the effect appeared to be the strongest when combining the mHealth app with non-personalized reminder messages (T2), followed by the case when using mHealth app alone (T1). Again, we found that providing additional personalized reminder messages can attenuate the mHealth treatment effect and lead to lower app usage by the patients – lower daily frequency of opening app and documenting health activities, lower frequency of communicating with medical experts, and lower loyalty rewards.

This is likely due to patient perceived intrusion, annoyingness and privacy concern (Pop-Eleches et al. 2011). Moreover, frequent personalized messages might cause the patients to feel increased control and judgment. Lack of choiceful and volitional feeling can lead to loss of autonomy and self-motivation (Deci and Ryan 1985, 2000). And correspondingly, it can lead to lower engagement in app usage.

**6.2 Mediation Effect of Patient Behavioral Change**

In addition to the above analyses, to further test the mediation effect of patient behavioral change on the health outcome, we conducted two additional mediation analyses using (1) a
simultaneous equation model, and (2) a directed acyclic graph (DAG) in the form of a parametric structural equation model (SEM).

First, we applied a simultaneous equation model to analyze the health outcome and the patient activities simultaneously. More specifically, we model the glucose change (i.e., post experiment – pre experiment) for each patient as a function of individual behavioral activities (i.e., exercises, food intake), demographics, and other control variables; in the meantime, we model the individual behavioral activities as a function of mHealth app treatment, while controlling for demographics and other factors. We provide the results in Tables F1a and F1b in Appendix F.

Second, we built a directed acyclic graph (DAG) in the form of a parametric structural equation model (SEM) to test the causal path of the mHealth impact on patient health outcome through the behavioral modification. In particular, we empirically test whether there is a statistically significant impact of mHealth adoption through the mediation effect of individual behavioral activities (i.e., exercises, food intake). We provide the estimation results in Figures F1a and F1b in Appendix F.

Overall, we found that the two additional mediation analyses using the simultaneous equation model and the directed acyclic graph (DAG) have demonstrated highly consistent evidence with our main results. They further support the causal impact of mHealth adoption on the health outcome, through the mediation effect of patient behavioral change.

6.3 Additional Follow-up Survey and Interview

To further verify our findings, we conducted an additional round of follow-up survey and interview. We provide the details in Appendix E. We asked the participants three major questions: (1) What is your favorite function of the blood glucose management mobile app? (2) How did these functions

---

13 Note that because control group C1 did not have access to the health application, we did not observe any individual-level behavioral activities from these patients. In the mediation analyses, control group C2 (who had access to the PC-based application) was used as the baseline for comparison.
help improve your health? (3) For participants in T3, what’s your feedback towards the personalized text messages about medical guidance based on your personal exercise, diet and health status?

Based on the survey user responses, the most useful app function liked by the users is “Learning about health knowledge (68%),” followed by “Health real-time tracking: blood glucose, exercise, drug, diet (67%),” “Personalized diabetes risk assessment (61%),” “Doctor consultation (53%),” and “Social network support (48%).”

When being asked how these functions helped improve their health, a large majority of the users mentioned that the app provided them a way to better monitor and “quantify” their life and health in real time, hence they were able to better manage food intake and exercise. For example, “The combination of my blood glucose level and exercise diet allows me to understand the relationship between them clearly, which motivates me to exercise more and eat healthier food”; “Self-tracking of health status provides a quantitative basis in real time, and thus improves my health level.”

Regarding the personalized text message about medical guidance, users raised three major concerns: (1) Interruption and annoyingness (58%), (2) Avoidance towards negative information (54%), and (3) Privacy (53%).

In addition to the survey responses, we have also conducted in-depth phone interviews with a randomly selected group of 7 experimental users from T3 treatment group. The main purpose of the interview was to further verify the survey responses, and meanwhile with a focus on why the personalized text messages did not work well.

We found the responses from the interview were highly consistent with those from the survey. When the participants were asked what functions they liked the most, all of the 7 interview participants indicated that the real-time health tracking function provided them a way of better monitoring and managing their health. They (and their family members) have also gained professional health knowledge through using the app.
When the participants were asked whether they liked the personalized medical guidance via text messages and why, a majority of them (6 out of 7) indicated that they found these personalized text messages “too frequent,” “annoying” and violating “privacy.”

Interestingly, during our interview one of the participants explicitly mentioned his/her preference of a less personalized text message to avoid “being judged all the time by someone.” This is highly consistent with our previous finding that frequent personalized messages might cause the patients to feel increased control and judgment. They can in turn lead to a significant decrease in patient intrinsic motivation of disease self-management and a lower health outcome.

6.4 Summary of Findings and Managerial Implications

Overall, our further analyses on patient glucose values, behavioral activities and app usage, together with the additional survey and interview, demonstrate highly consistent evidence that mobile health app platforms have a statistically significant impact on empowering patients with diabetes self-management, reducing patients’ glucose values, improving their lifestyle and health outcomes over time. Our results also provide strong evidence of the underlying behavioral mechanism that drives the observed health outcome.

More specifically, first, we find the adoption and usage of the mHealth platform has a significant impact on improving diabetes patient health outcomes as well as reducing medical costs. Second, between web-based and mobile-based platforms, we find a strong device effect: the mobile interventions led to a statistically significantly higher impact than the web-based intervention. Third, the mHealth platform also demonstrates a significantly stronger impact on patients’ dietary and lifestyle improvement as well as engagement with app usage than does the web-based platform. This finding suggests that patients in the mHealth treatment groups indeed became more engaged, motivated, and autonomously self-regulated with their health behavior over time. Such increased intrinsic motivation can in turn lead to an improvement in their health outcomes (e.g., glucose values,
hospital visits). This insight is critical. It provides strong evidence of the underlying mechanism that drives the observed health outcome, demonstrating the potential of mHealth in empowering diabetes patients for efficient health management.

Furthermore, in conjunction with patient self-management through the mHealth platform, we find heterogeneous effects between personalized and non-personalized messages. Interestingly, paired with all the health-management functions and resources provided by the mHealth platform, non-personalized SMS messages demonstrate on average the highest effect on reducing patient glucose over time. In contrast, personalization is not as effective as non-personalization if we try to improve diabetes patients’ engagement with the app usage or general life style (i.e., sleeping behavior or movement habits). This is likely due to patient perceived intrusion, annoyingness and privacy concern (Pop-Eleches et al. 2011). Furthermore, frequent personalized messages might cause the patients to feel increased control and judgment. They might cause patients to feel pressured or coerced by intrapsychic or interpersonal forces. We have seen such evidence in both our experimental analyses and our additional follow-up survey and interview (Appendix E).

Our finding is also highly consistent with prior research on Self-Determination Theory (SDT) and Cognitive Evaluation Theory (CET). Prior theoretical literature has demonstrated that lack of choiceful and volitional feeling can lead to loss of autonomy and self-motivation (Deci and Ryan 1985, 2000). It in turn can lead to a significant decrease in patient intrinsic motivation of self-management—demotivate patient behavior from being autonomously self-regulated in health. Such loss of autonomy can lead to lower patient engagement in the health self-management process (e.g., lower mHealth app usage, lower patient-physician engagement, lower compliance to medication and treatment). Also, prior research showed that pressured evaluations and imposed goals diminish intrinsic motivation because they conduce toward an external perceived locus of causality. In contrast, choice, acknowledgment of feelings, opportunities for self-direction, and positive social-contextual events
(e.g., feedback, communications, rewards) were found to enhance intrinsic motivation because they allow people a greater feeling of autonomy and competence (Deci & Ryan, 1985).

In sum, these findings are surprising and suggest frequent personalized mobile messaging may undermine the effectiveness of mHealth technology. The design of the mHealth platform, and health IT in general, is critical in achieving better patient engagement and health outcomes.

Our findings have several important implications. From the healthcare provider’s perspective, our study illustrates the importance of mHealth technology in facilitating diabetes patient self-management to improve well-being and health outcomes through behavioral modifications over time. Importantly, mHealth technology has shown great potential to improve patients’ compliance - following diets and executing life style changes that coincide with healthcare providers' recommendations for health and medical advice.

From the mHealth platform designer’s perspective, our study suggests the design of the mHealth platform is critical in achieving better patient engagement, empowerment, and health outcomes. Instead of personalized messaging, mHealth applications should be paired with non-personalized messaging with general knowledge about disease management for patient education. Our research also provides important design guidance for supporting communication and shared decision making via reminders, notifications and informed guidance, and improving care delivery operations to increase satisfaction and quality of care.

Finally, from the policy maker’s perspective, our findings demonstrate the potential of mHealth technologies in improving healthcare delivery to significantly impact outcomes, quality and costs. Our study also significantly improves the understanding of issues that interfere with patients' sustained engagement with mHealth apps and population adherence to treatment and wellness regimens. It provides key insights in the underlying mechanisms that drive individual and population health
behaviors and life style changes through mHealth app, and moreover, the critical policy implications regarding the adoption and sustained usage of mHealth technologies.

7. Robustness Analyses

We conducted several robustness analyses to check the validity of our experimental design and data quality. We discuss them in this section.

7.1 Long Recruitment Window

The rolling recruitment process in our study lasted for seven months. To guarantee that such long window would not introduce any confounding factors caused by time trend, first we have considered a time fixed effect in the individual-level Diff-in-Diff analysis (Time_t, coded as the time sequence index of patient glucose upload time) to control for any individual-level time trend. Moreover, in the analysis we have also controlled for the glucose type (before/after breakfast/lunch/dinner/sleep), the actual time, day and month indicators for the glucose upload time. This aims to control for any potential common time-of-day or seasonality effects for the entire population.

To further alleviate the concern, we have conducted an additional subsample analysis by selecting a subset of control and treatment groups who were recruited into our experiment during the same month. In particular, we focused on only those patients who were recruited in May 2015 (i.e., we chose the first month of the recruitment period to also minimize any potential risk of sample contamination). This led to a subsample of 285 patients: C1(n=49), C2(n=63), T1(n=57), T2(n=64), T3(n=52). We then conducted Diff-in-Diff analysis to compare the group means in the glucose change based on this subsample. Overall, our findings remain highly consistent based on the subsample analysis. The detailed results are provided in Table 8.

7.2 Sample Dropout

Indeed, high patient dropout rate is a common challenge in medical trials (e.g., Gupta et al. 2015). To alleviate any additional concern towards this issue, we conducted two levels of analyses: First, we compared the distributions of participants’ demographic and baseline health-related
characteristics between the dropout samples and the eligible samples. Based on a Welch's t-test, we could not reject the null hypothesis that there is no statistically significant difference between the two samples. The results are provided in Table 9.

Second, we compared the distributions of participants’ demographic and baseline health-related characteristics among all the dropout samples across the five experimental groups. We then conducted one-way ANOVA test and could not reject the null hypothesis that all the five groups are from the same sample distribution. The detailed results are provided in Table 10.

The results from the above two tests show that although dropout rate is non-negligible (~15%) in our study, the distribution of dropout samples remains quite consistent with that of the eligible samples, and moreover, the distribution of dropout samples remains quite consistent across the five experimental groups (i.e., missing data at random). Therefore, while we acknowledge this fact as one potential data limitation in our study, we are more confident that it is not a serious concern in affecting our results.

7.3 Validity Check for Self-Reported Data

Because medical information is sensitive, the accuracy of self-reported data is important for the validity of the results. We have validated our data using a multi-pronged approach.

First, our mHealth app partner provided an internal (full-time) medical expert team who helped review and validated the information about our experimental participants during the entire experimental period. In particular, as part of the risk assessment function, the internal medical team will communicate with each patient in person (mostly through phone calls) at least once every three months to carefully go over the historical (self-reported) records and the corresponding algorithm-generated diabetes risk score with the patient to better explain and validate the results. This validity check was done for all patients in C2, T1, T2 and T3 groups (who had access to the entire app functions through either PC or mobile devices). For patients in C1 group (who did not have access to the app), we checked the validity of their self-reported information during the surveys. In particular,
during the phone calls we went through all the self-reported glucose values with them and validate their answers in person.

Second, during pre- and post-treatment surveys we purposely asked the same set of questions regarding the demographics and historical medical conditions. This to some extent helped cross validate the accuracy of the information (i.e., it is less likely a person will remember exactly what he/she said 8 months ago if that was a lie). Besides, the surveys were conducted through phone calls. The spontaneous in-person conversation also helped our researchers to spot anything suspicious (e.g., an obvious lie).

Third, from an experimental design perspective, because our participants were fully randomized into the experimental groups, even if any potential noise might exist in the individual data, such noise effect would be minor and likely to cancel out across the experimental groups due to randomization.

Therefore, based on the above efforts, we are confident about the validity of our data and the accuracy of our final results.

8. Conclusion and Future Directions

In this paper, we have examined the emerging mHealth platform and its health and economic impacts on diabetes patient outcomes. To achieve our goal, we partnered with a real-world testbed in Asia that provides the nation’s largest mobile health app platform that specializes in diabetes care.

We have designed and implemented a large-scale randomized field experiment based on unique observations from 1,070 diabetes patients over three months together with a follow-up survey after five months. Our research demonstrates the adoption of the mHealth platform has a statistically significant impact on improving patients’ dietary and life style, leading to a reduction in patients’ blood glucose, hospital visits, and medical expenses over time.

Moreover, in conjunction with patient self-management through the mHealth platform, we also find heterogeneous effects between personalized and non-personalized messages. Interestingly, non-
personalized mobile messages with general diabetes-care guidance demonstrate a stronger impact on patient engagement with the app, behavior and life style change, and health improvement. Our study indicates the mHealth platform can have great potential for improving patients’ health outcomes, by assisting them with behavior modification and disease self-management. It also provides important insights into the design of the mHealth platform to achieve greater medical and economic outcomes.

On a broader note, our research will significantly improve our understanding of human behavior and interactions with smart and connected mHealth platforms, and broadly in the consumer Internet of Things (IOT). Digital health platform infrastructures are often the manifestation of complex technological and social systems (Eisenmann et al. 2011) and can have profound implications on social and economic transactions. However, how humans interact with the mHealth infrastructures is not as well understood. Our study can provide important managerial insights on issues that may influence individuals’ sustained engagement with mobile and wearable technology development, health and wellness, adherence to treatment and wellness regimens, the efficiency of healthcare delivery, and patient welfare. It will also improve our understanding of the key mechanisms that drive individual health and wellness behaviors and lifestyle changes through mobile and sensor technologies. Finally, it can provide critical policy implications regarding the design of smart digital health platforms through effective, sustained usage of these emerging technologies.

Our paper has some limitations, which can serve as fruitful areas for future research. First, in our data sample, the majority of the diabetes patients have type 2 diabetes (approximately 98%). Although type 2 diabetes accounts for approximately 90% to 95% of all diagnosed cases of diabetes, an examination of the mHealth impact on other types of diabetes with a larger sample in future would be useful. For example, given that the regular medication and insulin use could be a serious challenge

\[14\] http://www.healthline.com/health/type-2-diabetes/statistics
for type 1 diabetes patients, an examination of how mHealth can improve self-management and empowerment for such patients would be useful.

Second, in this current study, we have evaluated the mHealth app as a bundle of all the major functions. However, breaking down the overall application into different functional components (e.g., Behavior Tracking, Risk Assessment and Personalized Solution, Q&A, and Patient Community) and examining the health and economic impacts from each of them separately would be interesting.

Third, in this paper, we have not considered the potential impact related to the textual content of patient-physician communications, mainly because of potential privacy concerns blocking access to the textual content of the personal communications. However, based on our conversation with the testbed, we believe these patient-physician communications are highly professional and provide similar quality in medical guidance. In addition, in our analyses, we are able to control the frequency of the patient-physician communications.

Finally, our research focuses on the context of diabetes-care management. The methodologies and insights have the potential to be generalized to other chronic-disease and wellness-care contexts. However, examining other medical scenarios to compare the relationship and heterogeneity in the impact of the mHealth platform on patient behavior and outcomes under different healthcare contexts would be interesting and important for future research.
| Variable | Description                                      | Mean  | Std.  | Min  | Max  |
|----------|--------------------------------------------------|-------|-------|------|------|
| C1       | Dummy for control group 1                        | 0.15  | 0.33  | 0    | 1    |
| C2       | Dummy for control group 2 (Web)                  | 0.20  | 0.40  | 0    | 1    |
| T1       | Dummy for treatment group 1                      | 0.21  | 0.42  | 0    | 1    |
| T2       | Dummy for treatment group 2                      | 0.22  | 0.43  | 0    | 1    |
| T3       | Dummy for treatment group 3                      | 0.22  | 0.43  | 0    | 1    |
| Male     | Whether the patient is male                      | 0.65  | 0.47  | 0    | 1    |
| Age      | Numerical value of age                           | 55.17 | 8.91  | 23   | 72   |
| Age_30   | Dummy for age group <30                          | 0.24  | 0.43  | 0    | 1    |
| Age_30_40| Dummy for age group 31-40                        | 0.30  | 0.46  | 0    | 1    |
| Age_41_60| Dummy for age group 41-60                        | 0.39  | 0.49  | 0    | 1    |
| Age_60   | Dummy for age group >60                          | 0.06  | 0.24  | 0    | 1    |
| Married  | Whether the patient is married                    | 0.83  | 0.39  | 0    | 1    |
| Income   | Numerical value of income ($, annual)            | 76827.27 | 12258.67 | 29630 | 234524 |
| Income_50K| Dummy for income < 50K                          | 0.24  | 0.43  | 0    | 1    |
| Income_50_100K| Dummy for income 50-100K                   | 0.66  | 0.49  | 0    | 1    |
| Income_100_200K| Dummy for income 100,001-200K              | 0.09  | 0.29  | 0    | 1    |
| Income_200K| Dummy for income >200K                         | 0.01  | 0.11  | 0    | 1    |
| Pre-meal Glucose | Prior (most recent) pre-meal glucose value    | 7.23  | 1.83  | 3.2  | 18   |
| Post-meal Glucose | Prior (most recent) post-meal glucose value     | 9.86  | 4.36  | 4.2  | 30.7 |
| Hemoglobin     | Most recent glycated hemoglobin                   | 6.72  | 1.98  | 4.6  | 35   |
| Complication  | Whether there is a complication                 | 0.19  | 0.39  | 0    | 1    |
| Smoking       | Whether the patient is a smoker                  | 0.09  | 0.28  | 0    | 1    |
| Drinking      | Whether the patient drinks >140ml alcohol per week| 0.08  | 0.25  | 0    | 1    |
| Pregnant      | Whether the patient is pregnant                  | 0.01  | 0.12  | 0    | 1    |
| Other Major Disease | Whether the patient has other major diseases   | 0.01  | 0.11  | 0    | 1    |
| Type 2 Diabetes | Whether the patient has Type 2 diabetes          | 0.98  | 0.12  | 0    | 1    |
| Type 1 Diabetes | Whether the patient has Type 1 diabetes          | 0.01  | 0.11  | 0    | 1    |
| Gestational Diabetes | Whether the patient has gestational diabetes    | 0.01  | 0.12  | 0    | 1    |
| Diabetes Age  | Year(s) since diabetes was first diagnosed      | 5.40  | 5.14  | 0    | 28   |
| Uploaded Glucose | Patient self-uploaded real-time glucose (overall) | 7.18  | 2.07  | 3.1  | 34.3 |
| (Pre-meal)    | Patient self-uploaded real-time glucose (pre-meal) | 6.47  | 1.70  | 3.1  | 29.1 |
| (Post-meal)   | Patient self-uploaded real-time glucose (post-meal) | 8.17  | 2.18  | 3.9  | 34.3 |
| Upload_Morning| Whether uploading time is morning                | 0.36  | 0.48  | 0    | 1    |
| Upload_Afternoon| Whether uploading time is afternoon              | 0.15  | 0.36  | 0    | 1    |
| Upload_Night  | Whether uploading time is night                  | 0.49  | 0.50  | 0    | 1    |
| Hospital Visits | Number of hospital visits related to diabetes during the last 3 months | 2.64  | 6.69  | 0    | 12   |
| Medical Spending | Amount of medical spending related to diabetes during the last 3 months ($) | 57.14 | 63.49 | 20   | 1587.30 |
| Daily #Steps  | Number of steps walked per day                   | 3597.82 | 5123.67 | 1021 | 49926 |
| Daily Exercise Time | Daily exercise time (minutes)                  | 55.26  | 62.15  | 0    | 269.01 |
| Daily Exercise Calorie | Daily calories burned through exercise | 330.19 | 372.40 | 0 | 1720 |
|------------------------|----------------------------------------|--------|--------|---|------|
| Daily Food Calories    | Amount of calories consumed per day    | 1090.59| 169.11 | 438 | 2647 |
| Daily Sleeping Length  | Total daily sleeping time (minutes)    | 559.28 | 196.60 | 198 | 1380 |
| Weekly Late Night Sleep| # Nights per week when go to bed after 11pm | 1.97   | 4.21   | 0  | 7    |

### Patient App Usage

| Daily #Opening App      | Daily frequency of opening the app    | 1.14   | 0.43   | 0  | 6    |
|-------------------------|--------------------------------------|--------|--------|---|------|
| Daily #Activity Logs    | Daily frequency of activities documented through app | 1.32   | 4.65   | 0  | 34   |
| Weekly #Communications  | Weekly # of in-app communications with physicians | 1.94   | 3.26   | 0  | 9    |
| Weekly Loyalty Rewards  | Weekly loyalty rewards earned         | 19.43  | 241.32 | 0  | 35000|
| Weekly In-app Shopping  | Weekly in-app shopping for health products ($) | 25.97  | 180.60 | 0  | 2541.43|

#Observations on Uploaded Glucose Values: n=9,251, #patients n=1,070.
#Observations on Patient Activities and App Usage: n=55,359, #patients n=1,070.
Data Period: May 2015 – July 2016.
Table 2. Randomization Check – Demographic and Baseline Characteristics across 5 Groups

| Variable                  | C1 (n=156) | C2 (n=209) | T1 (n=230) | T2 (n=234) | T3 (n=241) | ANOVA  |
|---------------------------|------------|------------|------------|------------|------------|--------|
| **Age**                   |            |            |            |            |            |        |
| <30                       | 23%        | 22%        | 24%        | 21%        | 24%        | p<0.05 |
| 30-40                     | 31%        | 29%        | 26%        | 23%        | 21%        | p<0.05 |
| 41-60                     | 40%        | 42%        | 45%        | 51%        | 48%        | p<0.05 |
| >60                       | 6%         | 6%         | 5%         | 5%         | 6%         | p<0.05 |
| **Gender**                |            |            |            |            |            |        |
| Male                      | 65%        | 64%        | 65%        | 67%        | 66%        | p<0.05 |
| Female                    | 35%        | 36%        | 34%        | 34%        | 35%        | p<0.05 |
| **Married**               |            |            |            |            |            |        |
| 82%                       | 77%        | 90%        | 90%        | 86%        |            | p<0.05 |
| **Income ($, annual)**    |            |            |            |            |            |        |
| <50K                      | 26%        | 25%        | 27%        | 24%        | 27%        | p<0.05 |
| 50-100K                   | 66%        | 65%        | 62%        | 65%        | 64%        | p<0.05 |
| 100,001-200K              | 7%         | 8%         | 10%        | 10%        | 8%         | p<0.05 |
| >200K                     | 1%         | 1%         | 1%         | 1%         | 1%         | p<0.05 |
| **Baseline Condition**    |            |            |            |            |            |        |
| Pre-meal Glucose          | 7.11       | 7.04       | 6.90       | 7.13       | 6.95       | p<0.05 |
| Post-meal Glucose         | 8.43       | 8.59       | 8.44       | 8.38       | 8.68       | p<0.05 |
| Glycated Hemoglobin       | 7.03       | 6.98       | 6.60       | 6.67       | 6.82       | p<0.05 |
| Complication              | 19%        | 20%        | 17%        | 18%        | 16%        | p<0.05 |
| Smoking                   | 8%         | 9%         | 10%        | 9%         | 9%         | p<0.05 |
| Type 2 Diabetes           | 98%        | 96%        | 97%        | 96%        | 96%        | p<0.05 |
| Type 1 Diabetes           | 1%         | 2%         | 2%         | 2%         | 2%         | p<0.05 |
| Gestational Diabetes      | 1%         | 1%         | 2%         | 2%         | 2%         | p<0.05 |
| Diabetes Age              | 5.41       | 5.32       | 5.46       | 5.42       | 5.36       | p<0.05 |

**Note:** Data are in percentage or mean value. Percentages do not add up to 100% in some cases because of rounding. The majority of our patient samples belong to type 2 diabetes, which is the main focus of our study. Income is adjusted based on the local cost of living.

To better control for the potential variation in the patient-level characteristics, we also included all these variables in our primary analyses as control variables.
Table 3. Results from the Group Mean Analysis

| Treatment Group | Diff-Glucose | Diff-Hemoglobin | Diff-Hospital Visits (Recent 3Mons) | Diff-Spending (Recent 3Mons, USD) |
|-----------------|--------------|-----------------|------------------------------------|----------------------------------|
| C1 (n=156)      | -0.0287      | -0.0143         | -0.0283                            | -0.95                            |
| C2 (n=209)      | -0.5173      | -0.1967         | -0.0568                            | -5.70                            |
| T1 (n=230)      | -0.6291      | -1.0316         | -0.1208                            | -8.55                            |
| T2 (n=234)      | -0.6790      | -1.1612         | -0.1393                            | -11.55                           |
| T3 (n=241)      | -0.5746      | -0.9405         | -0.2264                            | -31.00                           |

Note: Values are calculated based on the difference between the two surveys (post-treatment value minus pre-treatment value). Glucose value is calculated based on an average across all glucose types. (Pairwise t-Test was conducted to test the pairwise difference between each two experimental groups for each of the four health outcome variables. The null hypothesis was rejected at P<0.05 for each comparison.)

Table 4. Estimation Results on Glucose Change from the Primary Diff-in-Diff Models

| Variables | Coef. (Std. Err.) | Coef. (Std. Err.) | Coef. (Std. Err.) | Coef. (Std. Err.) |
|-----------|-------------------|-------------------|-------------------|-------------------|
|           | I                 | II                | III               | IV                |
| Treatment Effect ($\beta_3$) |                |                    |                   |                   |
| $C2 \times Time_t$ | -0.3448** (0.1804) | -0.4606*** (0.1805) | -0.4105** (0.1819) | -0.5106** (0.2059) |
| $T1 \times Time_t$ | -0.4107*** (0.1553) | -0.4871*** (0.1588) | -0.4642*** (0.1589) | -0.5733*** (0.1832) |
| $T2 \times Time_t$ | -0.4589*** (0.1551) | -0.5327*** (0.1565) | -0.4588*** (0.1587) | -0.6170*** (0.1816) |
| $T3 \times Time_t$ | -0.3753** (0.1506) | -0.4669*** (0.1520) | -0.4243** (0.1531) | -0.5408** (0.1802) |
| $C2$ ($\beta_1$) | 1.4013 (1.5766) | 3.2889 (2.6396) | 1.5622 (0.9973) | 4.7363 (3.4386) |
| $T1$ ($\beta_1$) | 0.8605 (0.6704) | 0.8829 (0.6837) | 0.8565 (0.6912) | 1.1794 (1.0350) |
| $T2$ ($\beta_1$) | 0.8282 (0.6747) | 0.9042 (0.6893) | 0.9756 (0.6919) | 1.1432* (0.6361) |
| $T3$ ($\beta_1$) | 0.9583 (0.6784) | 0.9424 (0.6893) | 1.0193 (0.6893) | 1.2649* (0.6347) |
| $Time_t$ ($\beta_2$) | 0.3095** (0.1528) | 0.3920*** (0.1545) | 0.3674** (0.1559) | 0.4755*** (0.1822) |
| Intercept ($\beta_0$) | 13.3714*** (0.9649) | 11.4988*** (1.0279) | 11.8268*** (0.8336) | 10.5798*** (1.8447) |

Patient-Specific Control Variables ($X_i$)

Age, Married, Gender, Income, Prior Glucose, Prior Hemoglobin, Prior Medication, Other Disease, Complication, Smoking/Drinking, Pregnant, Diabetes Type, Interaction with Physicians. Yes Yes ---- ----

Patient-Time-Specific Control Variables ($C_{it}$)

Diabetes Age, Uploaded Glucose Type, Upload Time/Day/Month, Daily Exercise (#Steps), Daily App Usage (daily frequency of opening the app, daily frequency of documenting activity logs, weekly frequency of communications, weekly loyalty rewards and other in-app engagement like shopping). Yes ---- Yes ----

Note: * p<0.1, ** p<0.05, *** p<0.01. Errors are clustered at the experimental group level. Age and Income are in log form. Models I~IV include different sets of control variables. #patients=1,070, #observations=9,251.
Table 5. Estimation Results on Glucose Change Using Diff-in-Diff Model with Patient-Level Fixed Effects

| Variables                      | Coef. (Std. Err.)\(^\gamma\) | Coef. (Std. Err.)\(^\delta\) |
|--------------------------------|-------------------------------|-------------------------------|
| Treatment Effect \((\beta_2)\) |                               |                               |
| \(C2 \times Time_t\)          | -0.3327** (0.1704)            | -0.4267** (0.1977)            |
| \(T1 \times Time_t\)          | -0.3461** (0.1795)            | -0.4349** (0.1945)            |
| \(T2 \times Time_t\)          | -0.4909*** (0.1752)           | -0.5172*** (0.1703)           |
| \(T3 \times Time_t\)          | -0.4430** (0.1951)            | -0.4873** (0.1944)            |
| \(Time_t (\beta_1)\)          | 0.3557** (0.1732)             | 0.3936** (0.1572)             |
| Intercept \((\beta_0)\)        | 10.1937*** (1.7438)           | 7.3579*** (1.1258)            |

Patient-Time-Specific Control Variables \((C_{it})\)

Diabetes Age, Uploaded Glucose Type, Upload Time/Day/Month, Daily Exercise (#Steps), Daily App Usage (daily frequency of opening the app, daily frequency of documenting activity logs, weekly frequency of communications, weekly loyalty rewards and other in-app engagement like shopping).

Yes

Note: * p<0.1, ** p<0.05, *** p<0.01. Errors are clustered at experimental group level. Models I~ IV include different sets of control variables. #patients=1,070, #observations=9,251.

Table 6a. Estimation Results on Patient Activities Using Diff-in-Diff Model with Patient Fixed Effects

| Variables                      | Daily Food Calories Intake | Daily Exercise Time | Daily Exercise Calories | Daily #Steps Walked | Daily Sleeping Length | Weekly Freq of Late Night Sleep |
|--------------------------------|---------------------------|---------------------|--------------------------|---------------------|------------------------|---------------------------------|
|                                 | Coef. (Std. Err.)\(^A1\) | Coef. (Std. Err.)\(^A2\) | Coef. (Std. Err.)\(^A3\) | Coef. (Std. Err.)\(^A4\) | Coef. (Std. Err.)\(^A5\) | Coef. (Std. Err.)\(^A6\) |
| Treatment Effect                |                           |                     |                          |                     |                        |                                 |
| \(C2 \times Time_t\)           |                           |                     |                          |                     |                        |                                 |
| \(T1 \times Time_t\)           | -0.1803*** (0.0258)       | 0.0642** (0.0256)   | 0.0626** (0.0241)       | 0.0326** (0.0161)   | 0.1417** (0.0710)      | 0.0332 (0.0273)                 |
| \(T2 \times Time_t\)           | -0.1854*** (0.0227)       | 0.0688*** (0.0262)  | 0.0681** (0.0265)       | 0.0434*** (0.0168)  | 0.1814** (0.0719)      | 0.0306 (0.0283)                 |
| \(T3 \times Time_t\)           | -0.1843*** (0.0223)       | 0.0457* (0.0250)    | 0.0472** (0.0233)       | 0.0218* (0.0165)    | 0.1019* (0.0691)       | 0.0423* (0.0278)                |
| \(Time_t (\beta_1)\)           | 0.0197 (0.0234)           | -0.0331 (0.0274)    | -0.0135 (0.0221)        | 0.0102 (0.0162)     | -0.0298 (0.0575)       | -0.0115 (0.0245)                |
| Intercept \((\beta_0)\)        | 2.1149*** (0.0206)        | 1.1162*** (0.0229)  | 1.4566*** (0.0262)      | 1.3729*** (0.0175)  | 1.7192*** (0.0575)     | 0.4192*** (0.0302)              |

Note: * p<0.1, ** p<0.05, *** p<0.01. Errors are clustered at experimental group level. Models A1~A6 correspond to the following user activity outcome variables: A1 – (log) Daily food calories intake, A2 – (log) Daily exercise time (mins), A3 – (log) Daily exercise calories, A4 – (log) Daily #steps walked, A5 – (log) Daily sleeping length (mins), A6 – #Nights per week when the patient went to sleep later than 11pm.

#Patients=1,070, #Observations=55,359
### Table 6b. Estimation Results on Patient Activities Using Diff-in-Diff Model with Patient Fixed Effects and Additional Patient-Time-Specific Control Variables

| Variables | Daily Food Calories Intake | Daily Exercise Time | Daily Exercise Calories | Daily #Steps Walked | Daily Sleeping Length | Weekly Freq of Late Night Sleep |
|-----------|-----------------------------|---------------------|-------------------------|---------------------|-----------------------|-------------------------------|
|           | Coef. (Std. Err.)<sup>A1</sup> | Coef. (Std. Err.)<sup>A2</sup> | Coef. (Std. Err.)<sup>A3</sup> | Coef. (Std. Err.)<sup>A4</sup> | Coef. (Std. Err.)<sup>A5</sup> | Coef. (Std. Err.)<sup>A6</sup> |
| Treatment Effect | | | | | | |
| $C2 \times Time_t$ | ---- | ---- | ---- | ---- | ---- | ---- |
| $T1 \times Time_t$ | -0.1677*** | 0.0597** | 0.0601** | 0.0313** | 0.1399** | 0.0320 |
| (0.0243) | (0.0252) | (0.0240) | (0.0162) | (0.0711) | (0.0275) | |
| $T2 \times Time_t$ | -0.1724*** | 0.0602*** | 0.0692** | 0.0452*** | 0.1826** | 0.0329 |
| (0.0202) | (0.0268) | (0.0262) | (0.0169) | (0.0722) | (0.0288) | |
| $T3 \times Time_t$ | -0.1714*** | 0.0431* | 0.0455** | 0.0266* | 0.1112* | 0.0443* |
| (0.0204) | (0.0252) | (0.0235) | (0.0168) | (0.0694) | (0.0279) | |
| $Time_t (\beta_1)$ | 0.0183 | -0.0348 | -0.0132 | 0.0101 | -0.0275 | -0.0122 |
| (0.0219) | (0.0271) | (0.0222) | (0.0163) | (0.0577) | (0.0247) | |
| Intercept ($\beta_0$) | 1.9668*** | 1.1198*** | 1.4574*** | 1.3818*** | 1.7158*** | 0.4432*** |
| (0.0198) | (0.0226) | (0.0267) | (0.0177) | (0.0578) | (0.0305) | |

#### Patient-Time-Specific Control Variables:
Diabetes Age, Daily App Usage (daily frequency of opening the app, daily frequency of documenting activity logs, weekly frequency of communications, weekly loyalty rewards and other in-app engagement like shopping).

| Yes | Yes | Yes | Yes | Yes | Yes |

**Note:** *p<0.1, **p<0.05, ***p<0.01. Errors are clustered at experimental group level.

Models A1~A6 correspond to the following user activity outcome variables: A1 – (log) Daily food calories intake, A2 – (log) Daily exercise time (mins), A3 – (log) Daily exercise calories, A4 – (log) Daily #steps walked, A5 – (log) Daily sleeping length (mins), A6 – #Nights per week when the patient went to sleep later than 11pm. #Patients=1,070, #Observations=55,359
### Table 7. Estimation Results on App Usage Using Diff-in-Diff Model with Patient Fixed Effects

| Variables | Coef. (Std. Err.) | Coef. (Std. Err.) | Coef. (Std. Err.) | Coef. (Std. Err.) | Coef. (Std. Err.) |
|-----------|-------------------|-------------------|-------------------|-------------------|-------------------|
| Treatment Effect |                    |                    |                    |                    |                    |
| C2 × Time \(t\) | ---- | ---- | ---- | ---- | ---- |
| T1 × Time \(t\) | 0.1808*** (0.0190) | 0.2734*** (0.0873) | 0.0812*** (0.0059) | 0.2678* (0.1289) | -0.0023 (0.2652) |
| T2 × Time \(t\) | 0.1951*** (0.0190) | 0.2965*** (0.0881) | 0.0872*** (0.0058) | 0.2863* (0.1266) | 0.0375 (0.2879) |
| T3 × Time \(t\) | 0.1243*** (0.0185) | 0.2160** (0.0893) | 0.0241*** (0.0049) | 0.1557** (0.1240) | -0.1127 (0.3201) |
| Time \(t\) (\(\beta_1\)) | -0.0401** (0.0176) | -0.1626** (0.0797) | -0.1009*** (0.0051) | -0.1906* (0.1107) | 0.0870 (0.2035) |
| Intercept (\(\beta_0\)) | 1.0187*** (0.0167) | 2.2540*** (0.0802) | 1.2167*** (0.0058) | 2.0932*** (0.1224) | 0.8096** (0.3317) |

**Note:** * p<0.1, ** p<0.05, *** p<0.01. Errors are clustered at experimental group level. Models U1–U5 correspond to the following app usage outcome variables: U1 – (log) Daily frequency of opening the mHealth app, U2 – (log) Daily frequency of documenting activities through the app, U3 – Weekly frequency of communications with medical experts, U4 – (log) Weekly loyalty rewards earned, U5 – (log) Weekly shopping total purchase ($). #Patients=1,070, #Observations=55,359

### Table 8. Subsample Analysis (Patients Recruited in May 2015)

| Treatment | Diff-Glucose | Diff-Hemoglobin | Diff-Hospital Visits (Recent 3Mons) | Diff-Spending (Recent 3Mons, USD) |
|-----------|--------------|-----------------|-----------------------------------|----------------------------------|
| C1 (n=49) | -0.0338      | -0.0149         | -0.0297                           | -0.88                            |
| C2 (n=63) | -0.5202      | -0.1943         | -0.0601                           | -5.62                            |
| T1 (n=57) | -0.6312      | -1.0307         | -0.1319                           | -9.69                            |
| T2 (n=64) | -0.6978      | -1.1588         | -0.1443                           | -14.70                           |
| T3 (n=52) | -0.5889      | -0.9576         | -0.2098                           | -29.63                           |

**Note:** Values are calculated based on the difference between the two surveys (post-treatment value minus pre-treatment value). Glucose value is calculated based on an average across all glucose types. P<0.05 (ANOVA)
### Table 9. Comparison of Main Variables between Eligible Samples and Dropout Samples

| Variable        | Eligible Samples | Dropout Samples | t-test        |
|-----------------|-----------------|-----------------|---------------|
|                 | Mean | Std. | Mean | Std. |               |
| Male            | 0.65 | 0.47 | 0.63 | 0.49 | t = 1.39 (p<0.05) |
| Age             | 55.17 | 8.91 | 54.01 | 8.82 | t = 1.93 (p<0.05) |
| Married         | 0.83 | 0.39 | 0.79 | 0.35 | t = 1.65 (p<0.05) |
| Income          | 76827.27 | 12258.67 | 75403.57 | 13179.28 | t = 1.62 (p<0.05) |
| Pre-meal Glucose | 7.23 | 1.83 | 7.32 | 1.92 | t = 1.61 (p<0.05) |
| Post-meal Glucose | 9.86 | 4.36 | 9.95 | 4.22 | t = 0.68 (p<0.05) |
| Hemoglobin      | 6.72 | 1.98 | 6.81 | 1.87 | t = 1.49 (p<0.05) |
| Diabetes Age    | 5.40 | 5.14 | 5.11 | 5.02 | t = 1.85 (p<0.05) |

Eligible samples: #patients n=1,070. Dropout Samples: #patients n=273

### Table 10. Comparison of Main Variables among Dropout Samples across Five Experimental Groups

| Variable         | C1 Mean | C2 Mean | T1 Mean | T2 Mean | T3 Mean | ANOVA |
|------------------|---------|---------|---------|---------|---------|-------|
| Male             | 0.65    | 0.64    | 0.63    | 0.65    | 0.66    | p<0.05|
| Age              | 55.21   | 54.68   | 54.14   | 54.79   | 55.02   | p<0.05|
| Maried           | 0.83    | 0.81    | 0.80    | 0.81    | 0.79    | p<0.05|
| Income           | 76809   | 76092   | 75631   | 75395   | 78909   | p<0.05|
| Pre-meal Glucose | 7.21    | 7.27    | 7.32    | 7.24    | 7.36    | p<0.05|
| Post-meal Glucose| 9.89    | 9.82    | 9.91    | 9.94    | 9.86    | p<0.05|
| Hemoglobin       | 6.78    | 6.72    | 6.80    | 6.83    | 6.79    | p<0.05|
| Diabetes Age     | 5.38    | 5.25    | 5.16    | 5.21    | 5.19    | p<0.05|

Sample Size: C1(n=97), C2(n=92), T1(n=23), T2(n=35), T3(n=26)
References:

- Agarwal, R., J. Khuntia. 2009. Personal health information management and the design of consumer health information technology. Technical report, Publication 09-0075-EF, Agency for Healthcare Research and Quality, Rockville, MD.
- Agarwal, R., G. Gao, C. DesRoches, A. K. Jha. 2010. Research Commentary—The Digital Transformation of Healthcare: Current Status and the Road Ahead. Information Systems Research 21(4):796-809.
- Allegriante, J.P., Wells, M.T. and Peterson, J.C., 2019. Interventions to support behavioral self-management of chronic diseases. Annual review of public health, 40, pp.127-146.
- Allen JK, Stephens J, Dennison Himmelfarb CR, Stewart KJ, Hauck S. 2013. Randomized controlled pilot study testing use of smartphone technology for obesity treatment. J Obes; 151597.
- Amarasingham R, Plantinga L, Diener-West M, Gaskin DJ, Powe NR (2009) Clinical information technologies and inpatient outcomes: A multiple hospital study. Arch. Intern. Med. 169(2): 108–114.
- Anderson CL, Agarwal R (2011) The digitization of healthcare. Inform. Systems Res. 22(3):469–490.
- Angst, C., R. Agarwal, V. Sambamurthy, K. Kelley. 2010. Social contagion and information technology diffusion: The adoption of electronic medical records in U.S. hospitals. Management Sci. 56(8) 1219–1241.
- Aral S, Walker D. 2011. Creating social contagion through viral product design: A randomized trial of peer influence in networks. Management Science. 57(9):1623–1639.
- Aron R, Dutta S, Janakiraman R, Pathak PA (2011) Impact of automation of systems on medical errors. Inform. Systems Res. 22(3):429–446.
- Ayal, M., A. Seidmann. 2009. An empirical investigation of the value of integrating enterprise information systems: The case of medical imaging informatics. J. Management Inform. Systems 26(2) 43–68.
- Bardhan I, Thouin M (2013) Health information technology and its impact on the quality and cost of healthcare delivery. Decision Support Systems 55(2):438–449.
- Bardhan, I., Oh, J. H., Zheng, Z., and Kirksey, K. 2015. “Predictive Analytics for Readmission of Patients with Congestive Heart Failure,” Information Systems Research, 26(1): 19-39.
- Bhattacherjee, A., N. Hikmet, N. Menachemi, V. O. Kayhan, R. G. Brooks. 2007. The differential performance effects of healthcare information technology adoption. Inform. Systems Management 24(1) 5–14.
- Bodenheimer, T., Lorig, K., Holman, H., and Grumbach, K. 2002. “Patient Self-Management of Chronic Disease in Primary Care,” JAMA: The Journal of the American Medical Association, 288(19): 2469-2475.
- Bresnahan, T., J. Orsini and P. Yin. 2014. Platform Choice By Mobile App Developers. Working paper.
- Bresnahan, Timothy, and Shane Greenstein. 2014. Mobile Computing: The Next Platform Rivalry. American Economic Review, 104(5): 475-80.
- Buntin MB, Burke MF, Hoaglin MC, Blumenthal D (2011) The benefits of health information technology: A review of the recent literature shows predominantly positive results. Health Affairs 30(3):464–471.
• Campbell EM, Sittig DF, Ash JS, Guappone KP, Dykstra RH (2006). Types of unintended consequences related to computerized provider order entry. *J. Amer. Med. Informatics Assoc.* 13(5):547–556.
• CDC 2011. Centers for Disease Control and Prevention: National Diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States. Atlanta, Ga., U.S. Department of Health and Human Services, Centers for Disease Control and Prevention.
• Cebul RD, Love TE, Jain AK, Hebert CJ (2011) Electronic health records and quality of diabetes care. *New England J. Medicine.* 365(9):825–833.
• Clark, D.. Internet of Things' in Reach. The Wall Street Journal, Jan 5, 2014. http://online.wsj.com/news/articles/SB10001424052702303640604579296580892973264
• Das S, Yaylacicegi U, Menon NM (2011) The effect of information technology investments in healthcare: A longitudinal study of its lag, duration, and economic value. *IEEE Trans. Engrg. Management* 58(1):124–140.
• Deci, E. L., & Ryan, R. M. (1985). Intrinsic motivation and self-determination in human behaviour. New York: Plenum.
• Demidowich AP, Lu K, Tamler R, Bloomgarden Z. An evaluation of diabetes self-management applications for Android smartphones. *J Telemed Telecare.* 2012 Jun; 18(4):235-8.
• Eaton, B., S. Elaluf-Calderwood, C. Sorensen, and Y.. Yoo. 2015. Distributed Tuning of Boundary Resources: The Case of Apple's iOS Service System. *MISQ* 39(1), 217-243.
• Eisenmann, T, G. Parker, and M. Van Alstyne. 2011. Platform Envelopment. *Strategic Management Journal.* (32)1270-1285.
• Estrin, D and Sim, I. 2010. Open mHealth architecture: an engine for health care innovation. *Science.* 330: 759.
• Free, C, Phillips G, Galli L, Watson L, Felix L, Edwards P, et al. 2013. The Effectiveness of Mobile-Health Technology-Based Health Behaviour Change or Disease Management Interventions for Health Care Consumers: A Systematic Review. *PLoS Med* 10(1).
• Gao G, McCullough J, Agarwal R, Jha A (2010) A study of online physician ratings by patients. *Working paper,* R. H. Smith School of Business, University of Maryland, College Park.
• Garg, R., R. Telang. 2013. Inferring App Demand from Publicly Available Data. *MIS Quarterly* 37(4), 1253-1264.
• Ghose, A., A. Goldfarb, S. Han. 2013. How is the Mobile Internet Different? Search Costs and Local Activities, *Information Systems Research,* 24(3), 613-631.
• Ghose, A., P. Ipeirotis, B. Li. 2014. Examining the Impact of Ranking and Consumer Behavior on Search Engine Revenue, *Management Science.*60(7) 1632-1654.
• Ghose, A. and S. P. Han. 2014. Estimating demand for mobile applications in the new economy. *Management Science*.
• Goldfarb, A, Tucker C. 2011. Online display advertising: Targeting and obtrusiveness. *Marketing Science.* 30(3):389–404.
• Gray, B. M., J. L. Vandergrift, G. Gao, J. S. McCullough, R. S. Lipner. 2015. Website Ratings of Physicians and Their Quality of Care. *JAMA Intern Med.* 175(2):291-293.
• Gupta A, Calfas KJ, Marshall SJ, Robinson TN, Rock CL, Huang JS. 2015. Clinical trial management of participant recruitment, enrollment, engagement, and retention in the SMART study using a Marketing and Information Technology (MARKIT) model. *Contemp Clin Trials.* 42:185–95.
Han, S. P., S. Park, W. Oh. 2016. Mobile App Analytics: A Multiple Discrete-Continuous Choice Framework. Management Information Systems Quarterly. Forthcoming.

Harle CA., R. Padman, JS. Downs. 2008. The Impact Of Web-Based Diabetes Risk Calculators On Information Processing and Risk Perceptions. In Proceedings of AMIA Annual Symposium. pp. 283-287.

Harle CA, JS. Downs, R. Padman. 2012. Effectiveness of personalized and interactive health risk calculators: a randomized trial. Med Decis Making. Jul-Aug;32(4):594-605

Hitt, L. 2010. The effect of IT capital on hospital efficiency. Working paper, The Wharton School, University of Pennsylvania, Philadelphia.

Hoyle, R., M. Harris, C. Judd. 2001. Research Methods in Social Relations. Cengage Learning; 7th edition.

Hydari, M. Z., R. Telang, W.M. Marella. 2015. Saving Patient Ryan—Can Advanced Electronic Medical Records Make Patient Care Safer. Working paper.

Kane, G., R. G. Fichman, J. Gallaugher, J. Glaser. 2009. Community relations 2.0: With the rise of real-time social media, the rules about community outreach have changed. Harvard Bus. Rev. 87(11) 45–50.

Klein, WM., ME. Stefanek. 2007. Cancer risk elicitation and communication: lessons from the psychology of risk perception. CA: A Cancer Journal for Clinicians. May-Jun; 57(3):147-67.

Krisha S, Boren SA, Balas EA. Healthcare via cell phones: a systematic review. Telemed J E Health. 2009; 15(3):231–40.

Kwon, H. E., H. So, S. P. Han, W. Oh. 2016. Excessive Dependence on Mobile Social Apps: A Rational Addiction Perspective. Information Systems Research. Forthcoming.

Lancaster, K., Abuzour, A., Khaira, M., Mathers, A., Chan, A., Bui, V., Lok, A., Thabane, L., Dolovich, L., 2018. “The Use and Effects of Electronic Health Tools for Patient Self-Monitoring and Reporting of Outcomes Following Medication Use: Systematic Review,” Journal of Medical Internet Research, 20(12): e294

Lee, J. 2014. Hype or hope for diabetes mobile health applications? Diabetes Voice, 59, 43–46. Retrieved on 7/18/2016 from http://www.idf.org/sites/default/files/attachments/DV59-3-EN.pdf#page=47

Lee G. and Raghu T. S. 2014. Determinants of Mobile Apps Success: Evidence from App Store Market. Journal of Management Information System, 31(2):133-170.

Lee, G. M., J. Lee, A. B. Whinston. 2014. Matching Mobile Applications for Cross Promotion. Work paper.

Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, Chung MH. 2010. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet 376: 1838-45.

Lin, Y. K., V. Abhishek, J. Downs, R. Padman. 2016. Food for Thought: The Impact of m-Health Enabled Interventions on Eating Behavior. Working paper.

Liu, X., Zhang, B., Susarla, A., and Padman, R. 2019. “Go To YouTube and Call me in the Morning: Go To YouTube and Call Me in the Morning: Use of Social Media for Chronic Conditions,” forthcoming in MIS Quarterly

Maged N. Kamel Boulos, Ann C. Brewer, Chante Karimkhani, David B. Buller, and Robert P. Dellavalle. 2014. Mobile medical and health apps: state of the art, concerns, regulatory control and certification. Online J Public Health Inform. 2014; 5(3): 229.
• Martin CK, Miller AC, Thomas DM, Champagne CM, Han H, Church T. 2015. Efficacy of SmartLossSM, a smartphone-based weight loss intervention: results from a randomized controlled trial. Obesity (Silver Spring). 23:935–42.
• McCullough JS, Casey M, Moscovice I, Prasad S (2010) The effect of health information technology on quality in U.S. hospitals. Health Affairs 29(4):647–654.
• McKinsey 2013. Disruptive technologies: Advances that will transform life, business, and the global economy.
• Menon NM, Lee B, Eldenburg L (2000) Productivity of information systems in the healthcare industry. Inform. Systems Res. 11(1):83–92.
• Miller AR, Tucker CE (2011) Can health care information technology save babies? J. Political Econom. 119(2):289–324.
• Mohammed K. Ali, Ch.B., Kai McKeever Bullard, Jinan B. Saaddine, Catherine C. Cowie, Giuseppina Imperatore, and Edward W. Gregg. 2013. Achievement of Goals in U.S. Diabetes Care, 1999–2010. New England Journal of Medicine. 368:1613-1624.
• Myerson, Rebecca M., Lisandro D. Colantonio, Monika M. Safford, and Elbert S. Huang. 2018. Does Identification of Previously Undiagnosed Conditions Change Care-Seeking Behavior? Health services research. 53.3. 1517-1538.
• Nes AA, van Dulmen S, Eide E, Finset A, Kristjánsdóttir OB, Steen IS, Eide H. 2012. The development and feasibility of a web-based intervention with diaries and situational feedback via smartphone to support self-management in patients with diabetes type 2. Diabetes Res Clin Pract. 97(3):385–93.
• Nollen NL, Mayo MS, Carlson SE, Rapoff MA, Goggin KJ, Ellerbeck EF. 2014. Mobile technology for obesity prevention: a randomized pilot study in racial-and ethnic-minority girls. Am J Prev Med. 46:404–8.
• Patrick, H. and G. C Williams. 2012. Self-determination theory: its application to health behavior and complementarity with motivational interviewing. International Journal of Behavioral Nutrition and Physical Activity. 9:18
• Phillips, R. L. Jr. and A. W. Bazemore. 2010. Primary Care And Why It Matters For U.S. Health System Reform. Health Aff. vol. 29 no. 5 806-810.
• Pop-Eleches C, Thirumurthy H, Habyarimana JP, Zivin JG, Goldstein MP, de Walque D, et al., et al. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS 2011; 25: 825-34.
• Rossi MC, Nicolucci A, Pellegrini F, Brutomesso D, Bartolo PD, Marelli G, Dal Pos M, Galetta M, Horwitz D, Vespasiani G. 2009. Interactive diary for diabetes: a useful and easy-to-use new telemedicine system to support the decision-making process in type 1 diabetes. Diabetes Technol Ther. 11:19–24.
• Ryan, RM., Deci, E. L. (2000). "Self-determination theory and the facilitation of intrinsic motivation, social development, and well-being". American Psychologist. 55: 68–78.
• Ryan RM, Patrick H, Deci EL, Williams GC. 2008. Facilitating health behavior change and its maintenance: Interventions based on self-determination theory. The European Health Psychologist. 10:2-5.
• Schroeder SA. 2007. We can do better—Improving the health of the American people. New England Journal of Medicine. 357:1221-1228.
• Taubman, Sarah L., Heidi L. Allen, Bill J. Wright, Katherine Baicker, and Amy N. Finkelstein. "Medicaid increases emergency-department use: evidence from Oregon's Health Insurance Experiment." Science 343, no. 6168 (2014): 263-268.
• Uetake, K., N. Yang. 2017. Success Breeds Success: Weight Loss Dynamics in the Presence of Short-Term and Long-Term Goals. Working Paper.
• Wactlar, H., M. Pavel, W. Barkis. Can Computer Science Save Healthcare? 2011. CCC Blog. http://www.cccblog.org/2011/11/11/can-computer-science-save-healthcare/
• Wang, Q., B. Li, P. Wang. 2016. Using TB-Sized Data to Understand Multi-Device Advertising. In Proceedings of ICIS 2016.
• Wang, Q., B. Li, P. S. Singh. 2018. Copycats versus Original Mobile Apps: A Machine Learning Copycat Detection Method and Empirical Analysis. forthcoming, Information Systems Research.
• Wang, Y., Xue, H., Huang, Y., Huang, L., and Zhang, D. 2017. "A Systematic Review of Application and Effectiveness of mHealth Interventions for Obesity and Diabetes Treatment and Self-Management." Advances in Nutrition (8:3), pp. 449-462.
• Watson JM, Torgerson DJ. 2006. Increasing Recruitment to Randomised Trials: A Review of Randomised Controlled Trials. BMC Med Res Methodol. 6:34.
• Xu, K., J. Chan, A. Ghose, and S. Han. 2016. Battle of the Channels: The Impact of Tablets on Digital Commerce, forthcoming, Management Science.
• Yan, L. (2020). The Kindness of Commenters: An Empirical Study of the Effectiveness of Perceived and Received Support for Weight-Loss Outcomes. Production and Operations Management.
• Yan, L., and Tan, Y. (2014). Feeling Blue? Go Online: An Empirical Study of Online Supports among Patients. Information Systems Research, 25(4), 690-709.
• Yeary, Karen Hye-cheon Kim, Christopher R. Long, Pearl Anna McElfish. 2017. Design of a randomized, controlled, comparative-effectiveness trial testing a Family Model of Diabetes Self-Management Education (DSME) vs. Standard DSME for Marshallese in the United States. Contemporary clinical trials communications 6. 97-104.
• Zeevi, D., T. Korem, N. Zmora, D. Israeli, D. Rothschild, A. Weinberger, O. Ben-Yacov, D. Lador, T. Avnit-Sagi, M. Lotan-Pompan, J. Suez, J. A. Mahdi, E. Matot, G. Malka, N. Kosower, M. Rein, G. Zilberman-Schapira, L. Dohnalova, M. Pevsner-Fischer, R. Bikovsky, Z. Halpern, E. Elinav, and E. Segal. 2015. Personalized Nutrition by Prediction of Glycemic Responses. Cell. 163, pp 1079–1094.
• Zhang, Y., B. Li, X. Luo, and X. Wang. 2018. Personalized Mobile Targeting with User Engagement Stages: Combining Structural Hidden Markov Model and Field Experiment. Forthcoming, Information Systems Research. 2018.
• Zheng K, Padman R, Johnson MP, Diamond HS (2005) Understanding technology adoption in clinical care: Clinician adoption behavior of a point-of-care reminder system. Int. J. Medical Informatics 74(7–8):535–543.
Appendix A. Screenshots of Mobile/Web Interfaces

(1a) Overview of User Homepage
(1b) Adding a New Blood Glucose Value
(1c) User Behavior Tracking over Time.
(from left to right: Glucose, Blood pressure, Diet, and Exercise (Sports))
Figure A2. Screenshot of the Web Portal for Control Group C1 to Upload the Blood Glucose and Hemoglobin Values at the Beginning and End of the 3-month Treatment Period

Figure A3. Screenshots of the Behavior Recording Pages (Exercise and Diet)
Figure A4. Screenshots of the Diabetes Risk Assessment Pages

Figure A5. Screenshots of the Mobile Messages (Left: Non-personalized; Right: Personalized)
Appendix B. Survey Questionnaires

- Pre-experiment questionnaire

1. What is your last two pre-meal blood glucose values (mmol/L)?
   A. 6.1-9.1
   B. 9.1-12.1
   C. 12.1-15.1
   D. Over 15.1

2. What is your last two post-meal blood glucose values (mmol/L)?
   E. 6.1-9.1
   F. 9.1-12.1
   G. 12.1-15.1
   H. Over 15.1

3. What’s your age?
   A. Under 30 years old
   B. 30-40 years old
   C. 40-60 years old
   D. Over 60 years old

4. How much do you spend monthly for your diabetes treatment?
   A. Less than 2000 RMB
   B. 2000-5000 RMB
   C. 5000-10000 RMB
   D. More than 10000 RMB

5. How many types of medicine are you currently taking to treat diabetes?
   A. None
   B. 1-2
   C. 3-4
   D. 5 or more than 5

6. How often do you test your blood sugar?
   A. Once a day
   B. 2-3 times per day
   C. Once every 2-3 days
   D. Once a week
   E. Others

7. How do you evaluate your current diet?
   A. My diet is healthy and in line with the dietary requirements of people with diabetes.
   B. Quite regular, can eat three meals on time, can achieve less salt, less sugar, less oil
   C. Three meals a day, can be eaten on time, can try to achieve less salt, less sugar, less oil, but occasionally can’t.
   D. Three meals a day, but cannot control foods that eat less salt, less sugar, less oil.
   E. Three meals are irregular, but can control less salt, less sugar, less oil
   F. Three meals are irregular, unable to control diet

The questionnaires were translated from the original language into English for readability.
8. How do you think about healthy diet? (You can choose multiple options)
   A. Diet differentiation, eat more grains
   B. More pure natural food
   C. More fruit and vegetable
   D. Health care products, such as vitamin tablets
   E. I have no idea about healthy diet
   F. Others

9. Which of the following descriptions are appropriate for your daily workout? (You can choose multiple options)
   A. I exercise lightly every day, like walking
   B. I participate in fitness activities every day, such as running, playing Tai Chi, square dance, etc.
   C. I rarely participate in physical exercise, I rarely go out.
   D. I usually do high-intensity exercises, such as weight-bearing anaerobic exercise, and occasionally mild exercise, such as walking and playing Tai Chi.
   E. I usually do mild exercise and occasionally do high-intensity exercises.
   F. I don’t do any exercise.

10. Do you feel that your current exercise situation is conducive to the recovery of diabetes?
    A. Obvious effect
    B. General effect
    C. Almost no effect
    D. No idea

11. If jogging is good for your body every day, you can stick to it under the following conditions:
    A. If someone reminds you to jog every day
    B. If someone encourage you to jog every day
    C. If someone is running around every day
    D. Anyway, it’s hard to stick to

12. Which kind of emotions do you often have?\(^\text{16}\)
    A. Joyful and happy
    B. Feeling depressed
    C. Anxiety and depression
    D. Peaceful

13. Do you purchase and consume sugar-free health food for diabetics?
    A. Long-term consumption, regular purchase, fixed purchase location
    B. Occasionally eat, occasionally purchased, no fixed place to buy
    C. Seldom eat, there are patients recommended to try, there is no fixed place to buy
    D. Do not trust such products, think that you can stick to the kiln and diet, do not buy

14. Do you have the confidence to beat diabetes?
    A. Very confident
    B. General Confident
    C. Confident, but think it is hard

---

\(^{16}\) we asked the question about emotions mainly to screen participants who had unstable emotional status. We didn’t find any such case, so we didn’t include this variable in our main analysis.
D. Lack of confidence, but willing to try
E. Lack of confidence, barely maintain the status

15. Have you ever participated in a diabetes rehabilitation program or a similar health management program?
A. Yes, I have
B. No, I have not
C. No, but heard about that

16. What is your highest concern in health management? (You can choose multiple options)
A. Regular medical examination service
B. Personal health record establishment and management
C. Self-monitoring
D. Private doctor service
E. Personalized health management
F. Health guidance, lifestyle intervention and adjustment
G. Lecture, salon, party about heath management
H. Personal consultation service

17. Do you Smoke?
A. Yes
B. No

18. What type of diabetes do you have?
A. Type 1 diabetes
B. Type 2 diabetes
C. Gestational diabetes

19. How long do you have diabetes?
_________ Years

20. Have you had any complication?
A. Yes, please specify______________________
B. No

• Post-experiment questionnaire (end of the treatment period, and 5 months later)

1. What is your last two pre-meal blood glucose values (mmol/L)?
I. 6.1-9.1
J. 9.1-12.1
K. 12.1-15.1
L. Over 15.1

2. What is your last two post-meal blood glucose values (mmol/L)?
M. 6.1-9.1
N. 9.1-12.1
O. 12.1-15.1
P. Over 15.1

3. How many times did you visit the hospital during the last 3 months?
A. None
B. 1-3
C. 3-6
4. How many of these hospital visits were related to diabetes?
   A. 0
   B. 1-3
   C. 3-6
   D. 6-10
   E. More than 10

5. How much do you spend monthly for your diabetes treatment?
   E. Less than 2000 RMB
   F. 2000-5000 RMB
   G. 5000-10000 RMB
   H. More than 10000 RMB

6. What is your current solution to manage your blood sugar?
   A. Taking hypoglycemic drugs
   B. Insulin
   C. Diet management
   D. Sports management
   E. Daily life management (sufficient sleep, smoking cessation, alcohol restriction, etc.)

7. What kinds of drugs do you currently take? [Multiple choice questions]
   A. Metformin
   B. Acarbose
   C. Insulin
   D. Glipizide
   E. Gliclazide
   F. Gliclazone
   G. Rpaglinide
   H. Sitagliptin
   I. Others

8. How many times do you use the app every day? (only for treatment group)
   A. 0
   B. 1
   C. 2
   D. 3
   E. More than 3

9. Can you rate the app? (only for treatment group)
   A. 1 star
   B. 2 stars
   C. 3 stars
   D. 4 stars
   E. 5 stars
Appendix C. Overview of Randomization and Sampling

Figure C1. Randomization and Sampling Procedure
Appendix D. Time Trends

We examined the overall time trends in each experimental group regarding the blood glucose change over time at the individual patient level. We plot the glucose value over time for each group in Figure D1.

**Figure D1. Comparison of Time Trends for Blood Glucose Values over Time**

The Y-axis is the glucose value for each individual patient. The X-axis is the sequence number as the time indicator. We show the plots for both control groups and treatment groups at the individual level. From the time trend plots, we notice the three treatment groups on average uploaded more glucose values than the two control groups. This finding indicates a potential positive impact of mHealth in improving patient engagement with diabetes management. Furthermore, we see a noticeable downward trend over time in the three treatment groups compared to the two control groups. This finding suggests the mHealth platform seems to be able to help reduce patient glucose levels over time at the individual level. We also noticed an outlier in the T1 group at the very beginning, with a glucose value equal to 55. After consulting with the company and medical experts, we removed that sample from our primary model analysis.
Appendix E. An Additional Follow-up Survey and Interview

To better understand the causal mechanisms of our findings, we have conducted a new round of survey and interview in September 2019.

1. Summary of Survey Results.

First, we sent a survey to app users from the three treatment groups (T1-T3) in our experiment. We approached these participants via WeChat groups the mobile app company maintained over years. There were 610 treatment participants (out of 705 total participants from T1-T3) in the WeChat groups. We received a total of 124 responses to our survey. The response rate was 124/610 = 20.3%.

The detailed survey questionnaire was provided in the end of this Appendix. We asked the participants three major questions: (1) What is your favorite function of the blood glucose management mobile app? (2) How did these functions help improve your health? (3) For participants in T3, what’s your feedback towards the personalized text messages about medical guidance based on your personal exercise, diet and health status?

Based on the survey user responses, the most useful app function liked by the users is “Learning about health knowledge (68%),” followed by “Health real-time tracking: blood glucose, exercise, drug, diet (67%),” “Personalized diabetes risk assessment (61%),” “Doctor consultation (53%),” and “Social network support (48%).”

When being asked how these functions helped improve their health, a large majority of the users mentioned that the app provided them a way to better monitor and “quantify” their life and health in real time, hence they were able to better manage food intake and exercise. For example,

- “The blood glucose, exercise and diet tracking function provides me with a tool for daily health monitoring and comparison.”
- “The combination of my blood glucose level and exercise diet allows me to understand the relationship between them clearly, which motivates me to exercise more and eat healthier food.”
- “Self-tracking of health status provides a quantitative basis in real time, and thus improves my health level.”
- “Personalized recommendations for diet and exercise allow me to know exactly how many calories I should consume and how many I should burn.”
Regarding the personalized text message about medical guidance, users raised three major concerns: (1) Interruption and annoyingness (58%), (2) Avoidance towards negative information (54%), and (3) Privacy (53%). For example,

- “Receiving personalized text messages frequently makes me feel interrupted and the user experience is terrible.”
- “Sending personalized information frequently makes me feel terrible about my health, and too many negative emotions make me reluctant to try to change my health level.”
- “It makes me feel my privacy is being violated.”

2. Summary of Interview Results.

Second, in addition to the survey responses, we have also conducted in-depth phone interviews with a randomly selected group of 7 experimental users from T3 treatment group. The main purpose of the interview was to further verify the survey responses, and meanwhile with a focus on why the personalized text messages did not work well. The detailed question design of the interview was provided in the end of this Appendix.

We found the responses from the interview were highly consistent with those from the survey. When the participants were asked what functions they liked the most, all of the 7 interview participants indicated that the real-time health tracking function provided them a way of better monitoring and managing their health. They (and their family members) have also gained professional health knowledge through using the app. For example,

- “After using the app for some time, I have gained some health knowledge.”
- “The real-time tracking and the long-term blood glucose change trend helped me judge whether the medication, exercise or diet was reasonable and provided me a reference.”
- “You see, some people don't have a lot of knowledge about diabetes, right? People can gain some knowledge, and also have some reminders about their blood glucose management.”
- “I found the health tracking function is most useful for me. In daily life, it can help monitor my blood sugar.”
- “It can record my health data. I like this function most.”
- “It certainly doesn't make sense to people who are not sick, but it definitely makes sense to us who are sick, because we need such an assistant to let us know how high our blood sugar is at any time. We are very concerned about this.”
- “The most important one is the health knowledge. Because the patient's understanding of professional knowledge is still relatively inadequate. I have been learning a lot. Because I have had such instructions from the app, and my wife also has learned related knowledges and helped me.”
When the participants were asked whether they liked the personalized medical guidance via text messages and why, a majority of them (6 out of 7) indicated that they found these personalized text messages “too frequent,” “annoying” and violating “privacy.” For example,

- “The personalized message was sent too often. It’s better to have a longer interval.”
- “I think it’s a bit troublesome. I think the frequency of the personalize message was a little high.”
- “I can accept the personalized advice, but you better not send the reminders so often.”
- “If your blood glucose is in an expected range, you don’t need to be disturbed. Just when it’s abnormal (you can receive a personalized message intervention)”
- “It doesn't need to be reminded too often, just once every half a month. Because my blood sugar is now in a stable state.”
- “It feels that it knows what I do and feels like I am being watched by others.”

Very interestingly, during our interview one of the participants explicitly mentioned his/her preference of a less personalized text message to avoid “being judged all the time by someone”:

- “Is it possible for you to make these personalized guidance text messages sound less personal, but instead more systematic – like the ones automatically sent by the system, not humans? That would make me feel less stressful. Not like being judged by someone all the time, but simply like having an alarm clock.”

This is highly consistent with our previous finding that frequent personalized messages might cause the patients to feel increased control and judgment. They might cause patients to feel pressured or coerced by intrapsychic or interpersonal forces. Such lack of choiceful and volitional feeling can lead to loss of autonomy and self-motivation (Deci and Ryan 1985, 2000). It in turn can lead to a significant decrease in patient intrinsic motivation of disease self-management and a lower health outcome.

In summary, our additional analyses from the new survey and interview demonstrated high consistency to our previous results. They provided richer causal evidence to our findings. We found that the positive impact of mobile health app is largely due to the real-time tracking and health monitoring functions provided by the app. Such functions can help patients with better self-educating, self-monitoring, and self-managing their own health. Besides, users raised three major concerns
towards personalized health guidance via text messages: (1) Interruption and annoyingness, (2) Avoidance towards negative information, and (3) Privacy concern. Based on user responses, when mHealth apps are trying to combine text messages with app functions to deliver medical guidance, a less frequent (i.e., once or at most twice a month) and less personalized (i.e., should sound less personal but more systematic) text message is strongly preferred.

E1. Survey Questionnaire Design

Hello, Dear users! I'm Dr. XXX from XXX Thank you for registering our diabetes management mobile application before. In order to improve the user experience, we have a few questions for you, which are expected to take you for less than 10 minutes. We will compensate you for 10 yuan after you complete the questionnaire.

1. What is your favorite function of the blood glucose management APP? [multiple choice]
   A. Health Knowledge Function: health information
   B. Diabetes Risk Assessment Function
   C. Self-Tracking Function: blood glucose recording function; exercise recording function; drug recording function
   D. Professional Support Function: doctor consultation function; manual personalized information guidance
   E. Social Support Function: Patients’ moments (patients with diabetes can view the message posted by a friend)
   F. None of the above, my favorite function is ______________________

2. Did these functions help improve my health? If so, how? If not, why? Please specify.
   _________________

3. If we send you personalized guidance information via text messages based on your personal exercise and diet status, how would you feel? Do you think these personalized messages are helpful or not? Please specify.
   _________________

4. Do you have any other suggestions for the function module of the blood glucose management APP? Please specify.
   __________________

Your gender: [single choice]
A. Male
B. female
Your age: [single choice]
A. Under 18
B. 18-25
C. 26-30
D. 31-40
E. 41-50
F. 51-60
G. Over 60

Your current industry: [single choice]
A. IT / Software and Hardware Services / E-Commerce / Internet Operations
B. Fast Moving Consumer Goods (Food / Beverage / Cosmetics)
C. Wholesale / Retail
D. Apparel / Textiles / Leather
E. Furniture / Craft / Toy
F. Education / Training / Scientific Research / Institute
G. Home Appliance
H. Communication / Telecom Operation / Network Equipment / Value-added Service
I. Manufacturing
J. Automobile and Parts
K. Catering / Entertainment / Tourism / Hospitality / Life Service
L. Office Supplies and Equipment
M. Accounting / Auditing
N. Legal
O. Bank / Insurance / Securities / Investment Bank / Risk Fund
P. Electronic Technology / Semiconductor / Integrated Circuit
Q. Instrument / Industry Automation
R. Trade / Import & Export
S. Machinery / Equipment / Heavy Industry
T. Pharmaceutical / Biotechnology/ Medical Facilities / Equipment
U. Healthcare / Nursing / Health
V. Advertising / Public Relation / Media / Art
W. Publishing / Printing / Packaging
X. Real Estate Development / Construction Engineering / Decoration / Design
Y. Property Management / Business Center
Z. Agency / Consulting / Headhunting / Certification
AA. Transportation / Logistics
BB. Aerospace / Energy / Chemical
CC. Agriculture / Fishery / Forestry
DD. Other industries
E2. Interview Outline Design

1. Opening

Hello XXX, I am Dr. XXX from XXX. The purpose of this interview is to understand your attitude toward XX mobile app. This interview will take about twenty minutes. As compensation, we will pay you 20 yuan after the interview.

Your feedback and inputs are of great value to us. All your answers will be kept strictly confidential. We will not disclose your identity. All of your statements will only be used in research projects. If we want to cite any of your original words, we will use it in the form of a pseudonym.

2. Developing

1) Do you remember when you (refer to the registration time) registered your blood glucose mobile app?
2) What is your evaluation and impression of this blood glucose management app? What is your favorite function of diabetes management software? Why? Does these functions change your health behavior?
3) Did you receive a text message for a personalized diet and exercise guide? If so, how often?
4) Do you think these personalized text messages for health guidance helped with your health (or will help with your help if the patients have not received any)?
5) Do you think there are any disadvantages to your health caused by these text messages?
6) Would you like to cooperate with the staff to improve your eating and sports behaviors?
7) Would you like to receive a call or a text message from the company's nutritionist for active health guidance?
8) How often would you like to, if so?
9) What do you think is an acceptable personalized guidance program?
10) What do you think is the biggest pain point in the daily management of diabetes?

3. Ending

XXX, thank you very much for your help. I have no further questions. Your opinion is very helpful and enlightening to us. Thank you very much.
Appendix F. Mediation Analyses

To further test the mediation effect of patient behavioral change on the health outcome, we conducted two additional mediation analyses using (1) a simultaneous equation model, and (2) a directed acyclic graph (DAG) in the form of a parametric structural equation model (SEM).  

First, we applied a simultaneous equation model to analyze the health outcome and the patient activities simultaneously. More specifically, we model the glucose change (i.e., post experiment – pre experiment) for each patient as a function of individual behavioral activities (i.e., exercises, food intake), demographics, and other control variables; in the meantime, we model the individual behavioral activities as a function of mHealth app treatment, while controlling for demographics and other factors. We provide the results in Table F1a and Table F1b.

Table F1a. Estimation Results Using Simultaneous Equation Model – Exercise and Glucose

| Glucose Change (Post – Pre) | Coef. (Std. Err.)¹⁷ |
|-----------------------------|---------------------|
| Exercise Calories (log)     | -0.6935*** (0.0974) |
| Intercept                   | 10.8099*** (1.7367) |

Patient-Specific Control Variables

- Age, Married, Gender, Income, Prior Glucose, Prior Hemoglobin, Prior Medication, Other Disease, Complication, Smoking/Drinking, Pregnant, Diabetes Type, Interaction with Physicians, Diabetes Age, average Daily App Usage (daily frequency of opening the app, daily frequency of documenting activity logs, weekly frequency of communications, weekly loyalty rewards and other in-app engagement like shopping).

Exercise Calories (log)

|     | Coef. (Std. Err.)¹⁷ |
|-----|---------------------|
| T1  | 0.2148*** (0.0551)  |
| T2  | 0.2498** (0.1232)   |
| T3  | 0.1661*** (0.0678)  |
| Intercept | 5.0485*** (0.1348) |

Patient-Specific Control Variables

- Age, Married, Gender, Income, Prior Glucose, Prior Hemoglobin, Prior Medication, Other Disease, Complication, Smoking/Drinking, Pregnant, Diabetes Type, Interaction with Physicians, Diabetes Age, average Daily App Usage (daily frequency of opening the app, daily frequency of documenting activity logs, weekly frequency of communications, weekly loyalty rewards and other in-app engagement like shopping).

Note: * p<0.1, ** p<0.05, *** p<0.01. #patients=1,070, #observations=9,251.

¹⁷ Note that because control group C1 did not have access to the health application, we did not observe any individual-level behavioral activities from these patients. In the mediation analyses, control group C2 (who had access to the PC-based application) was used as the baseline for comparison.
Table F1b. Estimation Results Using Simultaneous Equation Model – Food Intake and Glucose

| Glucose Change (Post – Pre)                  | Coef. (Std. Err.) |
|----------------------------------------------|-------------------|
| Food Calories Intake (log)                   | 0.3760*** (0.1258) |
| Intercept                                    | 7.5798*** (1.4316) |

**Patient-Specific Control Variables**

Age, Married, Gender, Income, Prior Glucose, Prior Hemoglobin, Prior Medication, Other Disease, Complication, Smoking/Drinking, Pregnant, Diabetes Type, Interaction with Physicians. Diabetes Age, average Daily App Usage (daily frequency of opening the app, daily frequency of documenting activity logs, weekly frequency of communications, weekly loyalty rewards and other in-app engagement like shopping).

Food Calories Intake (log)

|       | Coef. (Std. Err.) |
|-------|-------------------|
| T1    | -0.5664*** (0.1540) |
| T2    | -0.8825*** (0.1402) |
| T3    | -0.2134*** (0.0251) |
| Intercept | -6.9580*** (2.0145) |

**Patient-Specific Control Variables**

Age, Married, Gender, Income, Prior Glucose, Prior Hemoglobin, Prior Medication, Other Disease, Complication, Smoking/Drinking, Pregnant, Diabetes Type, Interaction with Physicians. Diabetes Age, average Daily App Usage (daily frequency of opening the app, daily frequency of documenting activity logs, weekly frequency of communications, weekly loyalty rewards and other in-app engagement like shopping).

*Note:* * p<0.1, ** p<0.05, *** p<0.01. #patients=1,070, #observations=9,251.

Second, we built a directed acyclic graph (DAG) in the form of a parametric structural equation model (SEM) to test the causal path of the mHealth impact on patient health outcome through the behavioral modification. In particular, we empirically test whether there is a statistically significant impact of mHealth adoption through the mediation effect of individual behavioral activities (i.e., exercises, food intake). We provide the estimation results in Figures F1a and F1b.

In Figure F1a, C1 is dropped out of the model (hence no coefficient estimated associated with the arrow) because no behavioral activities were observed for this group. C2 is dropped out of the model because it is used as the baseline. The effects of mHealth adoption (T1, T2, T3) are highly consistent with our main analyses, demonstrating a statistically significant and positive impact on patients’ exercise activities (with the estimated coefficients 0.81, 0.88, 0.26, respectively), which in turn, leads to a lower blood glucose over time (with the estimated coefficient...
We also found a consistent trend where the combination of non-personalized SMS (T2) was the most effective, whereas the personalized SMS (T3) was the least effective.

Figure F1a. Directed Acyclic Graph (DAG) to Test the Mediation Effect of Exercise on Post-Experiment Blood Glucose Change.

We also conducted similar empirical test for the causal mediation effect of “Food Intake” and found consistent trend. As we see in Figure F1b, the effects of mHealth adoption (T1, T2, T3) demonstrate a statistically significant and negative impact on patients’ food calories intake (with the estimated coefficients -0.4, -0.26, -0.21, respectively), which in turn, leads to a higher blood glucose over time (with the estimated coefficient 0.19).

Figure F1b. Directed Acyclic Graph (DAG) to Test the Mediation Effect of Food Intake on Post-Experiment Blood Glucose Change
In sum, the two additional mediation analyses using the simultaneous equation model and the directed acyclic graph (DAG) further support the causal impact of mHealth adoption on the health outcome, through the mediation effect of patient behavioral change.